INHIBITOR OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR

Abstract: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth factor with high affinity but do not result in signal transduction. These soluble forms of the receptor bind VEGF and inhibit its function.

Description: TITLE OF THE DISCLOSURE INHIBITOR OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR BACKGROUND OF THE DISCLOSURE Recently a new class of cell-derived dimeric mitogens with selectivity for vascular endothelial cells has been identified and designated vascular endothelial cell growth factor (VEGF) . VEGF has been purified from conditioned growth media of rat glioma cells [Conn e al. , (1990), Proc. Natl. Acad. Sci. U.S.A., 82, pp 2628-2632]; and conditioned growth media of bovine pituitary folliculo stellate cells [Ferrara and Henzel, (1989), Biochem. Biophys. Res. Comm. , 161. pp. 851-858; Gozpadorowicz fit aL. , (1989), Proc. Natl. Acad. Sci. U.S.A., 86, PP- 7311-7315] and conditioned growth medium from human U937 cells [Connolly, D. T. et Al. (1989), Science, 2 , pp. 1309-1312]. VEGF is a dimer with an apparent molecular mass of about 46 kDa with each subunit having an apparent molecular mass of about 23 kDa. VEGF has some structural similarities to platelet derived growth factor (PDGF), which is a mitogen for connective tissue cells but not mitogenic for vascular endothelial cells from large vessels. The membrane-bound tyrosine kinase receptor, known as FLT, was shown to be a VEGF receptor [DeVries, C fit sl., (1992), Science, 25_5_, pp.989-991]. The FLT receptor specifically binds VEGF which induces mitogenesis. Another form of the VEGF receptor, designated KDR, is also known to bind VEGF and induce mitogenesis. The partial cDNA sequence and nearly full length protein sequence of KDR is known as well [Terman, B.I. et al., (1991) Oncogene fj., pp. 1677-1683; Terman, B.I. et al. , (1992) Biochem. Biophys. Res. Comm. 181, pp. 1579-1586]. Persistent angiogenesis may cause or exacerbate certain diseases such as psoriasis, rheumatoid arthritis, hemangiomas, angiofibromas, diabetic retinopathy and neovascular glaucoma. An inhibitor of VEGF activity would be useful as a treatment for such diseases and other VEGF-induced pathological angiogenesis and vascular permeability conditions, such as tumor vascularization. SUMMARY OF THE DISCLOSURE A naturally-occurring FLT messenger RNA (mRNA) was identified and cloned from vascular endothelial cells. This mRNA is shown to encode most of the extracellular, or soluble, portion of the VEGF receptor, FLT. Soluble receptor molecules including forms containing a C-terminal transmembrane region are also recombinantly engineered for this and other VEGF receptors. These soluble receptors, comprising truncated and modified forms are expressed in recombinant host cells and have VEGF binding properties. The soluble receptor proteins are useful as inhibitors of VEGF activity since they will bind available VEGF preventing it from activating its functional receptors on vascular endothelial cells and could form non-functional heterodimers with full-length membrane anchored VEGF receptors. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 - A schematic diagram of full length VEGF receptors (FLT and KDR) , the soluble VEGF receptors (sVEGF-RI and sVEGF-RII) and the soluble receptors containing the C-terminal transmembrane region (sVEGF-RTMI and sVEGF-RTMII) are shown with the protein domains of each. Figure 2 - The DNA sequence of the sVEGF-RI soluble VEGF receptor/VEGF inhibitor is shown. Figure 3 - The amino acid sequence of the sVEGF-RI soluble VEGF receptor/VEGF inhibitor is shown. Figure 4 - Demonstration that recombinant host cells express sVEGF-RI is shown by the formation of high molecular weight complexes of sVEGF-RI and [ 125 I]VEGF and separated by size exclusion chromatography. Figure 5 - A 12.57. polyacrylamide electrophoretic gel is shown which demonstrates the high degree of purity obtained for sVEGF-RI. Figure 6 - Cross-linked products of sVEGF-RI and [ 1 5 I]VEGF are shown at about 145 kDa, and at about 245 kDa. Figure 7A and 7B - Analysis of VEGF binding to sVEGF-RI (A) and corresponding Scatchard plot (B). Figure 8 - Inhibition of [ 125 I]VEGF binding to HUVECs by sVEGF-RI is demonstrated. Figure 9 - Inhibition of VEGF-mediated mitogenesis on HUVECs is shown using SVEGF-RI. Figure 10 - The nucleotide sequence encoding sVEGF-RII is shown. Figure 11 - The amino acid sequence for sVEGF-RII is shown. Figure 12 - The nucleotide sequence encoding sVEGF-RTMII is shown. Figure 13 - The amino acid sequence for sVEGF-RTMII is shown. Figure 14 - The nucleotide sequence encoding sVEGF-RTMI is shown. Figure 15 - The amino acid sequence for sVEGF-RTMI is shown. Figure 16 - A diagram of pmFLT is shown. Figure 17 - A diagram of pKDRA is shown. DETAILED DESCRIPTION OF THE DISCLOSURE The present invention relates to cDNA encoding a soluble VEGF receptor protein (sVEGF-R) which is isolated from VEGF receptor producing cells or is recombinantly engineered from VEGF receptor-encoding DNA. sVEGF-R, as used herein, refers to a protein which can specifically bind to a vascular endothelial cell growth factor without stimulating mitogenesis of vascular endothelial cells . The amino acid sequence of FLT is known, [Shibuya, M. e al. , (1990), Oncogene, 5_, pp.519-524] and corresponds to the full length cell-associated VEGF tyrosine kinase receptor. Other VEGF receptors are known to exist. Other known VEGF receptors include, but are not limited to KDR [Terman (1991), supra., and Terman (1992), supra.]. Mammalian cells capable of producing FLT, KDR and other VEGF receptors include, but are not limited to, vascular endothelial cells. Mammalian cell lines which produce FLT or KDR and other VEGF receptors include, but are not limited to, human endothelial cells. The preferred cells for the present invention include human umbilical vein endothelial cells (HUVEC). Other cells and cell lines may also be suitable for use to isolate sVEGF-R cDNA. Selection of suitable cells may be done by screening for sVEGF-R binding activity on cell surfaces, in cell extracts or conditioned medium or by screening for gene expression by PCR or hybridization. Methods for detecting soluble receptor activity are well known in the art [Duan, D-S. R. el fll., (1991) J.Biol.Chem. , 266, pp.413-418] and measure the binding of labelled VEGF. Cells which possess VEGF binding activity in this assay may be suitable for the isolation of sVEGF-R cDNA. Full length FLT producing cells such as human HUVEC cells (American Type Culture Collection, ATCC CRL 1730) [Hoshi, H. and McKeehan, W.L. , Proc. Natl. Acad. Sci. U.S.A., (1984) 81, pp. 6413-6417] are grown according to the recommended culture conditions of the ATCC. Full length FLT, and KDR VEGF receptors as well as extracellular region (sVEGF-RI and sVEGF-RII) and extracellular region plus transmembrane region forms (sVEGF-RTMI and sVEGF-RTMII) are shown in Figure 1. The full length receptor has an extracellular ligand binding region composed of about seven immunoglobulin-like domains, a membrane spanning sequence (transmembrane domain) and intracellular tyrosine kinase domains. The inhibitory forms of this receptor, which are the subject of the present invention, are also shown in Figure 1 and lack the intracellular kinase domains, and for some inhibitors, the transmembrane sequence and the C-terminal most Ig-like extracellular domain. Any of a variety of procedures may be used to molecularly clone sVEGF-R cDNA. These methods include, but are not limited to, direct functional expression of the sVEGF-R gene following the construction of an sVEGF-R-containing cDNA library in an appropriate expression vector system. Another method is to screen a sVEGF-R-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labelled oligonucleotide probe designed from the predicted amino acid sequence of sVEGF-R. The preferred method consists of screening a sVEGF-R-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding at least part of the full length FLT protein. This partial cDNA is obtained by the specific PCR amplification of sVEGF-R DNA fragments through the design of oligonucleotide primers from the known sequence of the full length FLT-encoding DNA. It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells or cell types, may be useful for isolating sVEGF-R-encoding DNA. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than HUVECs and genomic DNA libraries. It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have sVEGF-R activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate sVEGF-R cDNA may be done by first measuring secreted sVEGF-R activity using the VEGF binding assay described fully herein. Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Maniatis, T. , Fritsch, E.F. , Sambrook, J., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982). It is also readily apparent to those skilled in the art that DNA encoding sVEGF-R may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techiques can be found in Maniatis, T. , Fritsch, E.F. , Sambrook, J. in Molecular Cloning: A Laboratory Manuel (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982). Another means of obtaining sVEGF-R molecules is to recombinantly engineer them from DNA encoding the partial or complete amino acid sequence of a VEGF receptor. Examples of other VEGF receptors include, but are not limited to, KDR. Using recombinant DNA techniques, DNA molecules are constructed which encode at least a portion of the VEGF receptor capable of binding VEGF without stimulating mitogenesis. Standard recombinant DNA techniques are used such as those found in Maniatis, et _____ . , supra. Using one of the preferred methods of the present invention, cDNA clones encoding sVEGF-R are isolated in a two-stage approach employing polymerase chain reaction (PCR) based technology and cDNA library screening. In the first stage, DNA oligonucleotides derived from the extracellular domain sequence information from the known full length FLT, KDR or other VEGF receptor is used to design degenerate oligonucleotide primers for the amplification of sVEGF-R-specific DNA fragments. In the second stage, these fragments are cloned to serve as probes for the isolation of complete sVEGF-R cDNA from a commercially available lambda gtlO cDNA library (Clontech) derived from HUVEC cells (ATCC CRL 1730). These PCR derived products were used as hybridization probes for screening a lambda gtlO cDNA library derived from HUVECs (Clontech). Plating and plaque lifts of the library were performed by standard methods (T. Maniatis, E.F. Fritsch, J. Sambrook, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982). The probes were random-primed labelled with 32 P-dCTP to high specific activity and a separate screening of the library (1 x 10 6 plaques per screen) was conducted with each probe. The probes were added to hybridization buffer (50% formamide, 5X Denhardts, 6X SSC (IX SSC = 0.15 M NaCl, 0.015 M Na 3 citrate-2H 2 0, pH 7.0), 0.17_ SDS, 100 μg/ml salmon sperm DNA) at 1 x 10> cpm/ml. Four positively hybridizing phage were detected using the fit-specific probe. These positively hybridizing phage were observed to be less than full length fit. Two fit cDNA clones of about 2.0 kb and 2.7 kb in length were subcloned into pGEM vectors (Promega) and bi-directionally sequenced in their entirety by the chain termination method (Sanger ei ai. , (1977) P.N.A.S. USA, 74, pp. 5463-5467,) and shown to contain a single open reading frame of about 569 amino acids. Sequence analysis demonstrated that a portion of the 5' fit coding region was missing from these clones. The remainder of the 5' end was cloned using PCR and combined with the DNA of the clones lacking the 5' end to yield a single open reading frame encoding about 687 amino acids . The sequence for the cDNA encoding fit-derived sVEGF-RI is shown in Table 1, and was identified in clones 7 and 11. The deduced amino acid sequence of sVEGF-RI from the cloned cDNA is shown in Table 2. Inspection of the deduced amino acid sequence reveals the presence of a single, large open reading frame of 687 amino acids. By comparison with amino acid sequence of the full length FLT VEGF receptor, 31 amino acids are encoded at the C-terminal end of the cDNA which are different from those of FLT. Using another of the preferred methods of the present invention, DNA encoding sVEGF-R is constructed from a DNA sequence encoding a VEGF receptor. For purposes of illustration, DNA encoding the VEGF receptor known as KDR was utilized. Using the receptor DNA sequence, a DNA molecule is constructed which encodes the extracellular domain of the receptor, or the VEGF binding domain only and is denoted sVEGF-RII. Restriction endonuclease cleavage sites are identified within the receptor DNA and can be utilized directly to excise the extracellular-encoding portion. In addition, PCR techniques as described above may be utilized to produce the desired portion of DNA. It is readily apparent to those skilled in the art that other techniques, which are standard in the art, may be utilized to produce sVEGF-R molecules in a manner analagous to those described above. Such techniques are found, for example, in Maniatis e_l ______ . , supra. Additional truncated forms of the VEGF receptor are constructed which contain the transmembrane region. Retention of the transmembrane may facilitate orientation of the inhibitor molecule at the target cell surface. Examples of transmembrane region containing inhibitor molecules include but are not limited to those shown in Figure 1. sVEGF-RTMI and sVEGF-RTMII, as shown in Figure 1, are FLT-related and KDR-related, respectively, transmembrane region containing receptor inhibitors. Construction of transmembrane region containing molecules, such as sVEGF-RTMI and sVEGF-RTMII, is done by standard techniques known in the art including but not limited to utilizing convenient restriction endonuclease cleavage sites or PCR techniques as described herein. It is readily understood by those skilled in the art that various forms of the inhibitors of a VEGF receptor, as disclosed herein, containing only the extracellular region or containing, in addition, the transmembrane region may be constructed which have substantially the same activity. The cloned sVEGF-R cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant sVEGF-R. Techniques for such manipulations are fully described in Maniatis, T, e_t al. , supra, and are well known in the art. Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic genes in a variety of hosts such as bacteria, bluegreen algae, fungal cells, yeast cells, plant cells, insect cells and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal or bacteria-insect cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. A variety of mammalian expression vectors may be used to express recombinant sVEGF-R in mammalian cells. Commercially available mammalian expression vectors which may be suitable for recombinant sVEGF-R expression, include but are not limited to, pMClneo (Stratagene), pXTl (Stratagene), pSG5 (Stratagene), EB0-pSV2-neo (ATCC 37593) pBPV-l(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and gZD35 (ATCC 37565). DNA encoding sVEGF-R may also be cloned into an expression vector for expression in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to bacteria, yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to drosophila, moth, mosquito and armyworm derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CH0-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-l (ATCC CCL 26) and MRC-5 (ATCC CCL 171). Insect cell lines which may be suitable and are commercially available include but are not limited to 3M-S (ATCC CRL 8851) moth (ATCC CCL 80) mosquito (ATCC CCL 194 and 195; ATCC CRL 1660 and 1591) and armyworm (Sf9, ATCC CRL 1711). The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, liposome or protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce sVEGF-R protein. Identification of sVEGF-R expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-sVEGF-R antibodies, binding to radiolabelled VEGF, and the presence of host cell-secreted sVEGF-R activity. Expression of sVEGF-R DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred. Levels of sVEGF-R protein produced by host cells may be quantitated by immunoaffinity and/or ligand affinity techniques. sVEGF-R-specific affinity beads or sVEGF-R-specific antibodies are used to isolate 35 S-methionine labelled or unlabelled sVEGF-R protein. Labelled sVEGF-R protein is analyzed by SDS-PAGE. Unlabelled sVEGF-R protein is detected by Western blotting, ELISA or RIA assays employing sVEGF-R specific antibodies, or by ligand blotting with labelled VEGF. Following expression of sVEGF-R in a recombinant host cell, sVEGF-R protein may be recovered to provide sVEGF-R in active form, capable of binding VEGF without stimulating mitogenesis. Several sVEGF-R purification procedures are available and suitable for use. sVEGF-R may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, reversed phase chromatography, heparin sepharose chromatography, VEGF ligand affinity chromatography, and hydrophobic interaction chromatography. In addition, recombinant sVEGF-R can be separated from other cellular proteins by use of an immuno-affinity column made with monoclonal or polyclonal antibodies specific for full length sVEGF-R, or polypeptide fragments of sVEGF-R. Identification of sVEGF-RI - In an attempt to clone the VEGF receptor cDNA (fit) a HUVEC λgtlO cDNA library was screened with a DNA probe derived from the extracellular domain of the membrane bound or full length form of this receptor as shown in Figure 1. Four incomplete clones, all lacking various lengths of 5' coding sequence, were isolated from screening a total of 1 x 10^ plaques. Two of these isolates represent partial clones that were identical to full length fit, one of which contained the complete 3' coding region of the form described by Shibuya fit al- , supra. The other two clones were identical to full length fit up to base pair number 2219 (Table 1 and Figure 2) where they then diverged from full length fit. These clones (clone 7 and 11) coded for an additional unique 31 amino acids before the open reading frame is terminated by a TAA codon (Table 2 and Figure 3). Clone 7 and 11 coded for a protein with a predicted molecular mass of about 75 kDa containing 12 putative N-linked glycosylation sites. This version of the receptor was missing the transmembrane and intracellular kinase domains and thus coded for a natural soluble form of the VEGF receptor (sVEGF-RI). Further, the protein molecule predicted by sVEGF-RI has only the first six Ig-like domains, missing the one closest to the transmembrane sequence (Figure 1). The 31 amino acids at the C-terminal end of sVEGF-RI contain two cysteine residues, but does not resemble an Ig domain. Expression of sVEGF-RI in Sf9 cells - To analyze the binding and biological properties of this form of the receptor, the protein was expressed using a baculovirus expression system. Clone 7 was missing about 350 base pairs of coding sequence at the 5' end. This region was cloned by PCR using the primers described above and in Example 1. A clone containing the complete coding region of sVEGF-RI was constructed by combining the 5' PCR fragment with sVEGF-RI clone 7 which overlapped at a Sad site. The 5' EcoRl site was then changed to a BamHI site and the full length sVEGF-RI was cloned into pBluebac III (Invitrogen) as a BamHI/BamHI fragment. A recombinant baculovirus P-3 stock containing the sVEGF-RI gene 3' in relation to the polyhedrin promoter was then prepared as described herein. Culture media from small scale infections were tested for the ability to form high molecular weight complexes with [ 125 I]VEGF. The labeled ligand and culture media from the baculovirus infected cells were combined and incubated. The reactions were then analyzed by size exclusion chromatography. When the wild-type infected culture medium was mixed with the radioactive ligand (Figure 4) a single radioactive peak was observed. However, when the sVEGF-RI infected culture medium was used, a high molecular weight complex was formed, as evident by the appearance of a second peak in this reaction eluting near the void volume of the column. This experiment showed that the natural soluble form of the FLT VEGF receptor, sVEGF-RI, forms a high molecular weight complex with VEGF. The recombinantly produced sVEGF-R is purified from the recombinant host cell extracts or cell culture fluid using heparin-sepharose column chromatography which specifically binds the sVEGF-R protein. The " heparin-sepharose bound VEGF-R column is washed using a suitable buffer containing between 0.1M and 0.6M NaCl which removes contaminating proteins without significant loss of sVEGF-R. The sVEGF-R is eluted from the heparin-sepharose column using a suitable buffer containing about 1M NaCl, yielding substantially purified sVEGF-R. Binding of the sVEGF-RI to VEGF - The binding of 125 l-labelled VEGF to sVEGF-RI was characterized by crosslinking, and by complex formation with sVEGF-RI absorbed to 96 well plates. The crosslinked products are shown in Figure 6. The sVEGF-RI was cross-linked to [ 125 I]VEGF (lane 1); in the presence of unlabelled VEGF (lane 2) and unlabelled bFGF (lane 3). Two high molecular weight bands (about 145 kDa and 245 kDa) were formed in the sVEGF-RI and [ 12 ^I]VEGF containing reaction, and in the sVEGF-RI and [ 125 I]VEGF plus an excess of unlabelled bFGF reaction. The two high molecular weight bands were not present when sVEGF-RI was incubated with [ 125 I]VEGF plus an excess of unlabelled VEGF, demonstrating the specificity of sVEGF-RI for VEGF, and the ability of sVEGF-RI to form a dimer. The 5 145 kDa band is presumably a crosslinked complex containing one receptor molecule (about 100 kDa) and a VEGF dimer (about 46 kDa). As shown in Figure 6 complexes containing two receptor molecules (about 245 kDA) were also observed. This suggests that each VEGF 1° dimer can bind one or two receptor molecules and that the soluble form of the VEGF receptor may undergo ligand-induced dimerization. The affinity of sVEGF-RI for VEGF was evaluated by absorbing sVEGF-RI to the surface of a 96 i5 well plate, followed by blocking the nonspecific sites with 0.57β gelatin. Variable amounts of labeled ligand were added to each well. These results demonstrate that sVEGF-RI binds VEGF with high affinity with an apparent K d of about 20pM (Figure 7). Since the 0 soluble form of the receptor is missing the Ig domain closest to the transmembrane spanning region, this domain is not required for ligand binding. The sVEGF-RI is shown to inhibit binding of VEGF to HUVECs by incubating cultured HUVECs with 5 [125 ]VEGF and various amounts of sVEGF-RI. Following incubation, the cells are washed to remove unbound [ 125 I]VEGF. The cells are then solubilized and the amount of cell-associated --2-*i is determined by gamma counter, which demonstrates the amount of [^- 2 ^I]VEGF 0 which was capable of binding to the cellular VEGF receptor in. the presence of sVEGF-RI. Using this method, it is demonstrated that sVEGF-RI was capable of inhibiting [ 125 I]VEGF binding to HUVECs VEGF receptor (see Figure 8) . 5 Since sVEGF-RI was able to inhibit VEGF binding to cell receptors, it was then determined that sVEGF-RI could inhibit VEGF induced mitogenesis. Cells are preincubated with sVEGF-RI and then incubated with VEGF in the presence of [ 3 H]thymidine. Following 1° incubation, the amount of cellular DNA-incorporated [ 3 H]thymidine is measured which indicates whether VEGF has induced mitogenesis and caused [ 3 H]thymidine to be incorporated into cellular DNA. The presence of sVEGF-RI inhibits the ability of VEGF to stimulate I 5 mitogenesis as shown in Figure 9. The inhibitor of the present invention can be used for the inhibition of VEGF activity. The inhibitor can be used either topically or intravascularly. For topical applications the 2° formulation would be applied directly at a rate of about 10 ng to about 1 mg/cm 2 /day. For intravaneous applications, the inhibitor is used at a rate of about 1 μg to about 10 mg/kg/day of body weight. For internal use, the formulation may be released directly 5 into the region to be treated either from implanted slow release polymeric material or from slow release pumps or repeated injections. The release rate in either case is about 100 ng to about 100 μg/day/cm 3 . For non-topical application the VEGF 0 inhibitor is administered in combination with pharmaceutically acceptable carriers or diluents such as phosphate buffer, saline, phosphate buffered saline, Ringer's solution, and the like, in a pharmaceutical composition, according to standard pharmaceutical practice. For topical application, various pharmaceutical formulations are useful for the administration of the active compound of this invention. Such formulations include, but are not limited to, the following: ointments such as hydrophilic petrolatum or polyethylene glycol ointment; pastes which may contain gums such as xanthan gum; solutions such as alcoholic or aqueous solutions; gels such as aluminum hydroxide or sodium alginate gels; albumins such as human or animal albumins; collagens such as human or animal collagens; celluloses such as alkyl celluloses, hydroxy alkyl celluloses and alkylhydroxyalkyl celluloses, for example methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl methylcellulose, and hydroxypropyl cellulose; polyoxamers such as Pluronic® Polyols exemplified by Pluronic® F-127; tetronics such as tetronic 1508; and alginates such as sodium alginate. The following examples are provided as illustrative of the present invention without, however, limiting the same thereto. EXAMPLE 1 Cloning fit-related sVEGF-RI - A 580 base pair DNA probe for fit was obtained by PCR of the HUVEC phage library using the primers 5' GCACCTTGGTTGTGGCTGAC 3' (SEQ. ID. No.: 1) and 5' TGGAATTCGTGCTGCTTCCTGGTCC 3'(SEQ. ID. No.: 2). The resulting DNA fragment was cloned into pGEM3Z as a Xbal/EcoRI fragment. The probe was prepared by the random priming method [Feinberg, A.P. and Vogelstein, B. , (1983) Anal.Biochem. , 132. pp.6-13] using the megaprime kit (Amersham) at a specific activity of 1 X 10 7 cpm/ng. The HUVEC cDNA library was plated at a density of 5 X 10 4 plaques/150 cm plate then about 1 X 10 6 plaques were screened by hybridization as previously described [Maniatis, T. ≤±. al- , supra]. Briefly, following prehybridization at 42°C for 2 hours in 507o formamide, 5X SSC, 5X Denhardt's solution, 0.17_ SDS, 100 μg/ml salmon sperm DNA (hybridization buffer) the filters were hybridized with the probe for 16 hours at 42 β C in hybridization buffer. The filters were washed one time for 15 min at room temperature in 2X SSC then three times at 55°C in 0.1 X SSC. Four positive plaques were identified and rescreened two additional times to obtain homogeneous isolates. Inserts were cloned into pGEM3Z for DNA sequence analysis. Two of these clones were identified which contained less than the full length fit coding region. DNA sequence analysis showed that these clones lacked the 5' coding region of fit. The DNA sequence is shown in Table 1 and Figure 2, and the deduced amino acid sequence is shown in Table 2 and Figure 3. The 5' end of fit was cloned by PCR using the primers 5' GGAATTCCGCGCTCACCATGGTCAGC 3' (SEQ.ID.NO. :3) and 5' TTTGAATTCACCCGGCAGGGAATGACG 3' (SEQ.ID.NO. :4) . The PCR fragment generated with this set of primers was cloned into fit clone 7 as an EcoRI/SacI fragment. TABLE 1 GCGGACACTCCTCTCGGCTCCTCCCCGGCAGCGGCGGCGGCTCGGAGCGGGCTCCGGGG CTCGGGTGCAGCGGCCAGCGGGCCTGGCGGCGAGGATTACCCGGGGAAGTGGTTGTCTC CTGGCTGGAGCCGCGAGACGGGCGCTCAGGGCGCGGGGCCGGCGGCGGCGAACGAGAGG ACGGACTCTGGCGGCCGGGTCGTTGGCCGGGGGAGCGCGGGCACCGGGCGAGCAGGCCG CGTCGCGCTCACC ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC ACA GGA TCT AGT TCA GGT TCA AAA TTA AAA GAT CCT GAA CTG AGT TTA AAA GGC ACC CAG CAC ATC ATG CAA GCA GGC CAG ACA CTG CAT CTC CAA TGC AGG GGG GAA GCA GCC CAT AAA TGG TCT TTG CCT GAA ATG GTG AGT AAG GAA AGC GAA AGG CTG AGC ATA ACT AAA TCT GCC TGT GGA AGA AAT GGC AAA CAA TTC TGC AGT ACT TTA ACC TTG AAC ACA GCT CAA GCA AAC CAC ACT GGC TTC TAC AGC TGC AAA TAT CTA GCT GTA CCT ACT TCA AAG AAG AAG GAA ACA GAA TCT GCA ATC TAT ATA TTT ATT AGT GAT ACA GGT AGA CCT TTC GTA GAG ATG TAC AGT GAA ATC CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT ACG TCA CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT GGA AAA CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA GAA ATA GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT CTC ACA CAT CGA CAA ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC AAA TTA CTT AGA GGC CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG AGA GTT CAA ATG ACC TGG AGT TAC CCT GAT GAA AAA AAT AAG AGA GCT TCC GTA AGG CGA CGA ATT GAC CAA AGC AAT TCC CAT GCC AAC ATA TTC TAC AGT GTT CTT ° ACT ATT GAC AAA ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT AAA GCA TTC ATC ACT GTG AAA CAT CGA AAA CAG 5 CAG GTG CTT GAA ACC GTA GCT GGC AAG CGG TCT TAC CGG CTC TCT ATG AAA GTG AAG GCA TTT CCC TCG CCG GAA GTT GTA TGG TTA AAA 0 GAT GGG TTA CCT GCG ACT GAG AAA TCT GCT CGC TAT TTG ACT CGT 5 GGC TAC TCG TTA ATT ATC AAG GAC GTA ACT GAA GAG GAT GCA GGG AAT TAT ACA ATC TTG CTG AGC ATA AAA CAG TCA AAT GTG TTT AAA AAC CTC ACT GCC ACT CTA ATT GTC AAT GTG AAA CCC CAG ATT TAC GAA AAG GCC GTG TCA TCG TTT CCA GAC CCG GCT CTC TAC CCA CTG GGC AGC AGA CAA ATC CTG ACT TGT ACC GCA TAT GGT ATC CCT CAA CCT ACA ATC AAG TGG TTC TGG CAC CCC TGT AAC CAT AAT CAT TCC GAA GCA AGG TGT GAC TTT TGT TCC AAT AAT GAA GAG TCC TTT ATC CTG GAT GCT GAC AGC AAC ATG GGA AAC AGA ATT GAG AGC ATC ACT CAG CGC ATG GCA ATA ATA GAA GGA AAG AAT AAG ATG GCT AGC ACC TTG GTT GTG GCT GAC TCT AGA ATT TCT GGA ATC TAC ATT TGC ATA GCT TCC AAT AAA GTT GGG ACT GTG GGA AGA AAC ATA AGC TTT TAT ATC ACA GAT GTG CCA AAT GGG TTT CAT GTT AAC TTG GAA AAA ATG CCG ACG GAA GGA GAG GAC CTG AAA CTG TCT TGC ACA GTT AAC AAG TTC TTA TAC AGA GAC GTT ACT TGG ATT TTA CTG CGG ACA GTT AAT AAC AGA ACA ATG CAC TAC AGT ATT AGC AAG CAA AAA ATG GCC ATC ACT AAG GAG CAC TCC ATC ACT CTT AAT CTT ACC ATC ATG AAT GTT TCC CTG CAA GAT TCA GGC ACC TAT GCC TGC AGA GCC AGG AAT GTA TAC ACA GGG GAA GAA ATC CTC CAG AAG AAA GAA ATT ACA ATC AGA GGT GAG CAC TGC AAC AAA AAG GCT GTT TTC TCT CGG ATC TCC AAA TTT AAA AGC ACA AGG AAT GAT TGT ACC ACA CAA AGT AAT GTA AAA CAT TAA AGGACTCATTAAAAAGTAACAGTTGTCTCATATCATCTTGATTTATTGTCACTGTTG CTAACTTTCAGGCTCGGAGGAGATGCTCCTCCCAAAATGAGTTCGGAGATGATAGCA GTAATAATGAGACCCCCGGGCTCCAGCTCTGGGCCCCCCATTCAGGCCGAGGGGGCT GCTCCGGGGGGCCGACTTGGTGCACGTTTGGATTTGGAGGATCCCTGCACTGCCTTC TCTGTGTTTGTTGCTCTTGCTGTTTTCTCCTGCCTGATAAACAACAACTTGGGATGA TCCTTTCCATTTTGATGCCMCCTCTTTTTATTTTTAAGCGGCGCCCTATAGT (SEQ. ID. NO. : 5) TABLE 2 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gin His He Met Gin Ala Gly Gin Thr Leu His Leu Gin Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser He Thr Lys Ser Ala Cys Gly Arg Asn Gly Lys Gin Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gin Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala He Tyr He Phe He Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu He Pro Glu He He His Met Thr Glu Gly Arg Glu Leu Val He Pro Cys Arg Val Thr Ser Pro Asn He Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu He Pro Asp Gly Lys Arg He He Trp Asp Ser Arg Lys Gly Phe He He Ser Asn Ala Thr Tyr Lys Glu He Gly Leu Leu Thr Cyε Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gin Thr Asn Thr He He Asp Val Gin He Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gin Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg He Asp Gin Ser Asn Ser His Ala Asn He Phe Tyr Ser Val Leu Thr He Asp Lys Met Gin Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His He Tyr Asp Lys Ala Phe He Thr Val Lys His Arg Lys Gin Gin Val Leu Glu Thr Val Ala Gly Lys Arg Ser Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu Thr Arg Gly Tyr Ser Leu He He Lys Asp Val Thr Glu Glu Asp Ala Gly Asn Tyr Thr He Leu Leu Ser He Lys Gin Ser Asn Val Phe Lys Asn Leu Thr Ala Thr Leu He Val Asn Val Lys Pro Gin He Tyr Glu Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser Arg Gin He Leu Thr Cys Thr Ala Tyr Gly He Pro Gin Pro Thr He Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cyε Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe He Leu Asp Ala Asp Ser Asn Met Gly Asn Arg He Glu Ser He Thr Gin Arg Met Ala He He Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg He Ser Gly He Tyr He Cys He Ala Ser Asn Lys Val Gly Thr Val Gly Arg Asn He Ser Phe Tyr He Thr Asp Val Pro Asn Gly Phe His Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp He Leu Leu Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser He Ser Lys Gin Lys Met Ala He Thr Lys Glu His Ser He Thr Leu Asn Leu Thr He Met Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn Val Tyr Thr Gly Glu Glu He Leu Gin Lys Lys Glu He Thr He Arg Gly Glu His Cys Asn Lys Lys Ala Val Phe Ser Arg He Ser Lys Phe Lys Ser Thr Arg Asn Asp Cys Thr Thr Gin Ser Asn Val Lys His ••• (SEQ. ID. NO. : 6) EXAMPLE 2 Expression of sVEGF-RI in Sf9 insect cells - The full length sequence encoding sVEGF-RI was cloned as an EcoRl/BamHI fragment into pGEM3Z. The EcoRl site was then modified to a BamHI site and cloned into pBlueBac III 3' of the polyhedrin promoter (psFLTblue). This plasmid was transfected into Sf9 armyworm cells using liposomes . After 48 hours the medium from the transfected cells which contains recombinant polyhedrin virus particles, was harvested. Dilutions (10 3 - 10 4 fold) of the virus were prepared and plaque purified in soft agar containing 150 μg/ml 5-bromo-4-chloro-3- indolyl-β-D-galactoside. Recombinant plaques were identified by blue color and used to infect Sf9 cells (5 X 10 5 cells/well) in 12 well plates. Medium (100 μl) from polyhedrin minus infections was used to prepare P-2 viral stocks by infecting 2.5 X 10 6 cells in a T-25 flask. Large scale high titer P-3 viral stocks were then prepared by infecting Sf9 cells (500 ml at 2 X 10 6 cells/ml) with 5 ml of the P-2 stock then incubating at 27 e C for 5 - 6 days and the medium was harvested by centrifugation. Protein expression was accomplished by infecting cells at a density of 2- 2.5 X 10 6 cells/ml with a multiplicity of infection of 5 - 10. Twenty four hours after infection the cells were changed to a serum free medium (SF900II, Gibco BRL), incubated for an additional 48 hours and the medium was collected. This conditioned medium contains the recombinantly expressed sVEGF-RI protein. EXAMPLE 3 Iodination of VEGF - 12 ^I-labeled human recombinant VEGF was prepared by the chloramine T method (Hunter, W.M. and Greenwood, F.C., (1962) Nature (London), 194. pp. 495-496). Briefly, 1 μg of VEGF in 307. acetonitrile/0.17o trifluroacetic acid was adjusted to pH 7.1 by the addition of 1/3 volume of 0.4 M sodium phosphate buffer, pH 7.1. Freshly dissolved chloramine T (4 μl of a 2 mg/ml stock in 0.1 M sodium phosphate buffer, pH 7.1) was added to the VEGF solution and reacted for 45 seconds at room temperature (total volume of 150 μl). The reaction was stopped by the addition of 50 μl of 10 mM Kl and 50 μl of 2 mg/ l meta bisufite. The labeled ligand was separated from the free 125 l by gel filtration on a 0.7 X 15 cm Sephadex G-25 column equilibrated in PBS with 1 mg/ml gelatin. Fractions were counted in a Packard γ counter, aliquoted and stored at -70°C. VEGF was labeled to a specific activity of 5 x 10^ to 1 x 10 6 cpm/ng. Gel Filtration Chromatography - Receptor-ligand complex was formed by incubating 10 μl of 125 l-labeled VEGF (10^ cpm) with 100 μl of either wild-type or baculovirus sVEGF-RI-containing, infected Sf9 cell culture medium overnight at room temperature. The reaction products were separated on a Sephacryl S200 gel filtration column (0.7 X 25 cm) equilibrated in PBS, 1 mg/ml gelatin, at a flow rate of 15 ml/hr. Fractions (0.75 ml) were collected and analyzed in a γ counter. Receptor-ligand complexes pass quickly through the column while the free labelled VEGF passes through more slowly. The results of this experiment shown in Figure 4 demonstrate the formation of a high molecular weight complex between labelled VEGF and sVEGF-RI protein. This shows that sVEGF-RI binds VEGF. Crosslinking - Purified sVEGF-RI (1-lOng) was added to 25 μl of binding buffer (Dulbecco's Modified Eagle's medium (DME), 25 mM HEPES, pH 7.5, 0.37. gelatin), and 1 x 10 5 cpm of [ 125 I]-VEGF was added (Figure 6, lane 1) with either 200ng of unlabelled VEGF (lane 2) or bFGF (lane 3), then incubated 2 to 16 hours at room temperature. Bis(sulfosuccinimidyl)suberate (Pierce) crosslinker was added to a final concentration of 1 mM. The reaction was stopped after 15 min by the addition of boiling SDS PAGE sample buffer. The crosslinked products were separated by SDS PAGE on a 7.57. acrylamide gel and analyzed either by autoradiography or a phosphoimager. The results are shown in Figure 6 and demonstrate that sVEGF-RI binds labelled VEGF by the appearance of two bands of about 145 kDa and 245 kDa. The 145 kDa band consists of one sVEGF-RI molecule and one VEGF molecule (Monomer, M.). The 245 kDa band apparently consists of two sVEGF-RI molecules and one VEGF dimer (D) . Free VEGF ligand (L) dimers migrated at about 45 kDA. Binding assay - The binding of sVEGF-RI to VEGF was analyzed using a 96 well plate assay as described by Duan, D-S. R. f it al., supra. Briefly, sVEGF-RI, 50 to 200 μl partially purified by Mono Q chromatography (Pharmacia), was diluted to 10 ml in 25 mM TRIS, pH 7.4, 100 mM NaCl, 20 mM NH HC0 3 . Aliquots (100 μl) were absorbed to the surface of a 96 well plate for 18 hours at 4°C, the plates were then washed twice with blocking buffer (DME, 25 mM HEPES, pH 7.5, 0.57. gelatin) and the nonspecific sites were blocked in the same buffer for 6 hours at 4 β C. The plate was then washed twice in binding buffer. Various amounts of [l 2 5i]VEGF were added to the wells in a final volume of 100 μl/well and incubated for 2 hours at room temperature. The wells were washed three times with 100 μl of binding buffer, the bound protein was solubilized with 100 μl of 17. SDS, 0.57. BSA and counted in a γ counter. The results, shown in Figure 7, were analyzed by the method of Scatchard [Scatchard, G. , (1949) Ann. N.Y. Acad. Sci., 5., pp. 660-672]. The analysis demonstrates that sVEGF-RI retains high affinity binding for VEGF with a K d value of about 20 pM. This clearly demonstrates that sVEGF-RI, lacking the transmembrane region and adjacent Ig-like domain, binds VEGF with high affinity and that these regions are not required for VEGF binding. EXAMPLE 4 Inhibition of VEGF binding by sVEGF-RI - The ability of sVEGF-RI to inhibit VEGF binding to HUVECs was tested. HUVECs were plated at 50,000 cells/well in 24 well plates precoated with gelatin, and allowed to grow to confluence. A constant amount of [ 125 I]VEGF (100,000 cpm) was mixed with various amounts of partially purified sVEGF-RI in binding buffer, in a total volume of 200 μl and preincubated at room temperature for 1 hour. Samples were added to the cells and incubated for 4 hours at 4°C with shaking. The medium was then aspirated and the cells were washed three times with binding buffer. The bound radioactivity was solubilized with 50 mM TRIS-HC1, pH 8.0, 150 mM NaCl, 17. NP40, 17. BSA and counted in a γ counter. The results are shown in Figure 8. At the highest concentration of sVEGF-RI, VEGF binding to HUVECs was reduced by 707.. It may, however, be difficult to completely inhibit binding to the cellular membrane bound receptor since one molecule of sVEGF-R bound to a VEGF dimer may be able to bind to cell associated receptor to form an inactive (sVEGF-RI)-VEGF-(membrane spanning VEGF receptor) complex. EXAMPLE 5 Inhibition of VEGF mediated mitogenesis bv sVEGF-RI Mitogenic inhibition - Since sVEGF-RI was able to inhibit VEGF binding to endothelial cells, it was then determined that the soluble receptor could inhibit VEGF induced mitogenesis in HUVECs. HUVECs were plated in gelatin coated 96 well plates at a density of 4000 cells/well in 100 μl of DME supplemented with 107. heat inactivated fetal calf serum plus antibiotics (penicillin G, 100 units/ml; streptomycin sulfate, 100 μg/ml). After 16 hours the medium was changed and test samples were added, cells were preincubated with a variable amount of purified sVEGF-RI for 15 minutes at 37 β C before growth factor (10 ng/ml) was added. The cells were incubated for 24 hours then [methyl- 3 H]thymidine (0.8 μCi/well; 20 Ci/mmol: ICi = 37 GBq, final specific activity of 0.8 μCi/nmole) was added followed by incubated for an additional 72 hours at 37°C under 57. CO2• The cells were then washed twice with Hank's balanced salt solution adjusted to pH 7.5 with 25 mM Hepes, 0.17. BSA. The cells were then lysed, the DNA was solubilized with 0.2 M Na 2 C0 3 , 0.1 M NaOH, and [ 3 H]thymidine incorporation was quantified by scintillation counting. The results are shown in Figure 9. sVEGF-RI was able to completely inhibit VEGF induced [ 3 H]thymidine incorporation in HUVECs. EXAMPLE 6 Purification of baculovirus expressed sVEGF-RI from Sf9 cells - Culture medium from Sf9 cells infected with a baculovirus construct designed to express sVEGF-RI (Example 2) was chromatographed through a heparin Sepharose CL-6B (Pharmacia) column (0.7 X 4 cm). The column was washed with 5 volumes of 10 mM Na-phosphate buffer, pH 6.2, 0.1 M NaCl, followed by 6 ml of 10 mM Na-phosphate buffer, pH 6.2, 0.6 M NaCl. The sVEGF-RI was eluted with 10 mM Na-phosphate buffer, pH 6.2, 1.0 M NaCl. Polyacrylamide gel electrophoresis was performed which demonstrated greater than 907. purity (as judged by coomassie blue staining) of the recombinantly produced sVEGF-R (Figure 5). The identity of the protein was confirmed by N-terminal protein sequence analysis. The actual N-terminus (Ser Lys Leu ... ) of the recombinant protein differs by two amino acids from that predicted by Shibuya et al., supra. (Ser-Ser-Ser... ) . The peptidase cleavage site in sVEGF-RI produced in Sf9 cells was between residues gly-26 and ser-27. EXAMPLE 7 Construction of KDR-related sVEGF-R - Soluble forms of KDR (a known VEGF receptor) [Terman, B.I. et al. , (1991) Oncogene 6 , pp. 1677-1683; Terman, B.I. et al. , (1992) Bioche . Biophys. Res. Comm. 187, pp. 1579-1586] may exist naturally but have not yet been identified. A soluble form of KDR is recombinantly constructed by ° modifying its coding sequence by PCR using the primers 1) 5' TTTTGGATCCCTGCAGACAGATCTACGTTTGAGAACC 3' (SEQ. ID. NO. : 7) and 2) 5' TTTTGGATCCTTAACGCTCTAGGACTGTGAGC 3' (SEQ. ID. NO.: 8), and pKDRA (the Xhol/EcoRl fragment coding for the extracellular and transmembrane 5 domain of KDR cloned into the EcoRl site of pGEM 7Z obtained from Promega) as a template (Figure 17). This generated a translation stop codon after amino acid residue number 663 of KDR which corresponds to the extracellular domain of full length KDR. This modified 0 fragment is then used to replace the Pstl/BamHl fragment of pKDRA generating a truncated form of the KDR gene (Figure 10) which codes for a soluble receptor denoted sVEGF-RII (Figure 11). The Xhol site at base pair number 257 is then changed to a BamHI site by 5 standard cloning techniques. Another truncated form of the KDR receptor is created with primer 1 shown above, and primer 3) 5' TTTTGGATCCAACGGTCCCTAGGATGATGAC 3' , (SEQ. ID. NO.: 9) (Figure 12). This form of KDR, denoted sVEGF-RTMII, is truncated at the C-terminal side of the transmembrane domain and therefore retains the transmembrane region (Figure 13). A similar form of the FLT receptor is generated by PCR using the primers 4) 5' AGCACCTTGGTTGTGGCTGACTC 3' (SEQ. ID. NO.: 10) and 5) 5' TTTTGGATCCTTAGATAAGGAGGGTTAATAGG 3' (SEQ. ID. NO.: 11) and plasmid pmFLT (full length fit cloned 5 into the EcoRI site of pGEM3Z obtained from Promega) as a template (Figure 16). The 780 base pair PCR fragment can then be cloned together with the EcoRl/Xbal fragment from pmFLT to produce an EcoRl/BAMHl fragment (Figure 14) encoding a truncated form of FLT (denoted 1° sVEGF-RTMI) which retains the transmembrane domain but lacks the cytoplasmic domain (Figure 15). The EcoRl site at the 5' end of the gene is then modified to a BamHI site. The resulting truncated forms of KDR and FLT are then cloned into pBluebaclll (Stratagene) for i5 expression in Sf9 insect cells. Characterization of these constructed truncated forms of VEGF receptors is accomplished by the techniques used to characterize sVEGF-RI as in Examples 2, 3, 4, 5, and 6. 20 5 0 SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Thomas, Kenneth A. Kendall, Richard L. (ii) TITLE OF INVENTION: INHIBITOR OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (iii) NUMBER OF SEQUENCES: 18 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Merck & Co., Inc. (B) STREET: P.O. Box 2000 126 E Lincoln Avenue (C) CITY: Rahway (D) STATE: NJ (E) COUNTRY: USA (F) ZIP: 07065-0907 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Wallen, John W.III (B) REGISTRATION NUMBER: 35,403 (C) REFERENCE/DOCKET NUMBER: 18888 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (908) 594-3905 (B) TELEFAX: (908) 594-4720 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:1: GCACCTTGGT TGTGGCTGAC 20 (2) INFORMATION FOR SEQ ID N0:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2: TGGAATTCGT GCTGCTTCCT GGTCC 25 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3: GGAATTCCGC GCTCACCATG GTCAGC 26 (2) INFORMATION FOR SEQ ID N0:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: si gle (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4: TTTGAATTCA CCCGGCAGGG AATGACG 27 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2313 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5: GCGGACACTC CTCTCGGCTC CTCCCCGGCA GCGGCGGCGG CTCGGAGCGG GCTCCGGGGC 60 TCGGGTGCAG CGGCCAGCGG GCCTGGCGGC GAGGATTACC CGGGGAAGTG GTTGTCTCCT 120 GGCTGGAGCC GCGAGACGGG CGCTCAGGGC GCGGGGCCGG CGGCGGCGAA CGAGAGGACG 180 GACTCTGGCG GCCGGGTCGT TGGCCGGGGG AGCGCGGGCA CCGGGCGAGC AGGCCGCGTC 240 GCGCTCACCA TGGTCAGCTA CTGGGACACC GGGGTCCTGC TGTGCGCGCT GCTCAGCTGT 300 CTGCTTCTCA CAGGATCTAG TTCAGGTTCA AAATTAAAAG ATCCTGAACT GAGTTTAAAA 360 GGCACCCAGC ACATCATGCA AGCAGGCCAG ACACTGCATC TCCAATGCAG GGGGGAAGCA 420 GCCCATAAAT GGTCTTTGCC TGAAATGGTG AGTAAGGAAA GCGAAAGGCT GAGCATAACT 480 AAATCTGCCT GTGGAAGAAA TGGCAAACAA TTCTGCAGTA CTTTAACCTT GAACACAGCT 540 CAAGCAAACC ACACTGGCTT CTACAGCTGC AAATATCTAG CTGTACCTAC TTCAAAGAAG 600 AAGGAAACAG AATCTGCAAT CTATATATTT ATTAGTGATA CAGGTAGACC TTTCGTAGAG 660 ATGTACAGTG AAATCCCCGA AATTATACAC ATGACTGAAG GAAGGGAGCT CGTCATTCCC 720 TGCCGGGTTA CGTCACCTAA CATCACTGTT ACTTTAAAAA AGTTTCCACT TGACACTTTG 780 ATCCCTGATG GAAAACGCAT AATCTGGGAC AGTAGAAAGG GCTTCATCAT ATCAAATGCA 840 ACGTACAAAG AAATAGGGCT TCTGACCTGT GAAGCAACAG TCAATGGGCA TTTGTATAAG 900 ACAAACTATC TCACACATCG ACAAACCAAT ACAATCATAG ATGTCCAAAT AAGCACACCA 960 CGCCCAGTCA AATTACTTAG AGGCCATACT CTTGTCCTCA ATTGTACTGC TACCACTCCC 1020 TTGAACACGA GAGTTCAAAT GACCTGGAGT TACCCTGATG AAAAAAATAA GAGAGCTTCC 1080 GTAAGGCGAC GAATTGACCA AAGCAATTCC CATGCCAACA TATTCTACAG TGTTCTTACT 1140 ATTGACAAAA TGCAGAACAA AGACAAAGGA CTTTATACTT GTCGTGTAAG GAGTGGACCA 1200 TCATTCAAAT CTGTTAACAC CTCAGTGCAT ATATATGATA AAGCATTCAT CACTGTGAAA 1260 CATCGAAAAC AGCAGGTGCT TGAAACCGTA GCTGGCAAGC GGTCTTACCG GCTCTCTATG 1320 AAAGTGAAGG CATTTCCCTC GCCGGAAGTT GTATGGTTAA AAGATGGGTT ACCTGCGACT 1380 GAGAAATCTG CTCGCTATTT GACTCGTGGC TACTCGTTAA TTATCAAGGA CGTAACTGAA 1440 GAGGATGCAG GGAATTATAC AATCTTGCTG AGCATAAAAC AGTCAAATGT GTTTAAAAAC 1500 CTCACTGCCA CTCTAATTGT CAATGTGAAA CCCCAGATTT ACGAAAAGGC CGTGTCATCG 1560 TTTCCAGACC CGGCTCTCTA CCCACTGGGC AGCAGACAAA TCCTGACTTG TACCGCATAT 1620 GGTATCCCTC AACCTACAAT CAAGTGGTTC TGGCACCCCT GTAACCATAA TCATTCCGAA 1680 GCAAGGTGTG ACTTTTGTTC CAATAATGAA GAGTCCTTTA TCCTGGATGC TGACAGCAAC 1740 ATGGGAAACA GAATTGAGAG CATCACTCAG CGCATGGCAA TAATAGAAGG AAAGAATAAG 1800 ATGGCTAGCA CCTTGGTTGT GGCTGACTCT AGAATTTCTG GAATCTACAT TTGCATAGCT 1860 TCCAATAAAG TTGGGACTGT GGGAAGAAAC ATAAGCTTTT ATATCACAGA TGTGCCAAAT 1920 GGGTTTCATG TTAACTTGGA AAAAATGCCG ACGGAAGGAG AGGACCTGAA ACTGTCTTGC 1980 ACAGTTAACA AGTTCTTATA CAGAGACGTT ACTTGGATTT TACTGCGGAC AGTTAATAAC 2040 AGAACAATGC ACTACAGTAT TAGCAAGCAA AAAATGGCCA TCACTAAGGA GCACTCCATC 2100 ACTCTTAATC TTACCATCAT GAATGTTTCC CTGCAAGATT CAGGCACCTA TGCCTGCAGA 2160 GCCAGGAATG TATACACAGG GGAAGAAATC CTCCAGAAGA AAGAAATTAC AATCAGAGGT 2220 GAGCACTGCA ACAAAAAGGC TGTTTTCTCT CGGATCTCCA AATTTAAAAG CACAAGGAAT 2280 GATTGTACCA CACAAAGTAA TGTAAAACAT TAA 2313 (2) INFORMATION FOR SEQ ID N0:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 687 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6: Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1 5 10 15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30 Glu Leu Ser Leu Lys Gly Thr Gin His lie Met Gin Ala Gly Gin Thr 35 40 45 Leu His Leu Gin Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro 50 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser He Thr Lys Ser Ala 65 70 75 80 Cys Gly Arg Asn Gly Lys Gin Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 95 Ala Gin Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100 105 110 Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala lie Tyr He Phe He 115 120 125 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu He Pro Glu 130 135 140 He He His Met Thr Glu Gly Arg Glu Leu Val He Pro Cys Arg Val 145 150 155 160 Thr Ser Pro Asn He Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 175 Leu He Pro Asp Gly Lys Arg He He Trp Asp Ser Arg Lys Gly Phe 180 185 190 He He Ser Asn Ala Thr Tyr Lys Glu He Gly Leu Leu Thr Cys Glu 195 200 205 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220 Gin Thr Asn Thr He He Asp Val Gin He Ser Thr Pro Arg Pro Val 225 230 235 240 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255 Pro Leu Asn Thr Arg Val Gin Met Thr Trp Ser Tyr Pro Asp Glu Lys 260 265 270 Asn Lys Arg Ala Ser Val Arg Arg Arg He Asp Gin Ser Asn Ser His 275 280 285 Ala Asn He Phe Tyr Ser Val Leu Thr He Asp Lys Met Gin Asn Lys 290 295 300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 305 310 315 320 Ser Val Asn Thr Ser Val His He Tyr Asp Lys Ala Phe He Thr Val 325 330 335 Lys His Arg Lys Gin Gin Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340 345 350 Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val 355 360 365 Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu 370 375 380 Thr Arg Gly Tyr Ser Leu He He Lys Asp Val Thr Glu Glu Asp Ala 385 390 395 400 Gly Asn Tyr Thr He Leu Leu Ser He Lys Gin Ser Asn Val Phe Lys 405 410 415 Asn Leu Thr Ala Thr Leu He Val Asn Val Lys Pro Gin He Tyr Glu 420 425 430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser 435 440 445 Arg Gin He Leu Thr Cys Thr Ala Tyr Gly He Pro Gin Pro Thr He 450 455 460 Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470 475 480 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe He Leu Asp Ala Asp Ser 485 490 495 Asn Met Gly Asn Arg He Glu Ser He Thr Gin Arg Met Ala He He 500 505 510 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg 515 520 525 He Ser Gly He Tyr He Cys He Ala Ser Asn Lys Val Gly Thr Val 530 535 540 Gly Arg Asn He Ser Phe Tyr He Thr Asp Val Pro Asn Gly Phe His 545 550 555 560 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser 565 570 575 Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp He Leu Leu 580 585 590 Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser He Ser Lys Gin Lys 595 600 605 Met Ala He Thr Lys Glu His Ser He Thr Leu Asn Leu Thr He Met 610 615 620 Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625 630 635 640 Val Tyr Thr Gly Glu Glu He Leu Gin Lys Lys Glu He Thr He Arg 645 650 655 Gly Glu His Cys Asn Lys Lys Ala Val Phe Ser Arg He Ser Lys Phe 660 665 670 Lys Ser Thr Arg Asn Asp Cys Thr Thr Gin Ser Asn Val Lys His 675 680 685 (2) INFORMATION FOR SEQ ID N0:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7: TTTTGGATCC CTGCAGACAG ATCTACGTTT GAGAAC 36 (2) INFORMATION FOR SEQ ID N0:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8: TTTTGGATCC TTAACGCTCT AGGACTGTGA GC 32 (2) INFORMATION FOR SEQ ID N0:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ( X i) SEQUENCE DESCRIPTION: SEQ ID N0:9: TTTTGGATCC AACGGTCCCT AGGATGATGA C 31 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i ) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:10: AGCACCTTGG TTGTGGCTGA CTC 23 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:11: TTTTGGATCC TTAGATAAGG AGGGTTAATA GG 32 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 661 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: l near (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gin His He 1 5 10 15 Met Gin Ala Gly Gin Thr Leu His Leu Gin Cys Arg Gly Glu Ala Ala 20 25 30 His Lys Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu 35 40 45 Ser He Thr Lys Ser Ala Cys Gly Arg Asn Gly Lys Gin Phe Cys Ser 50 55 60 Thr Leu Thr Leu Asn Thr Ala Gin Ala Asn His Thr Gly Phe Tyr Ser 65 70 75 80 Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser 85 90 95 Ala He Tyr He Phe He Ser Asp Thr Gly Arg Pro Phe Val Glu Met 100 105 110 Tyr Ser Glu He Pro Glu He He His Met Thr Glu Gly Arg Glu Leu 115 120 125 Val He Pro Cys Arg Val Thr Ser Pro Asn He Thr Val Thr Leu Lys 130 135 140 Lys Phe Pro Leu Asp Thr Leu He Pro Asp Gly Lys Arg He He Trp 145 150 155 160 Asp Ser Arg Lys Gly Phe He He Ser Asn Ala Thr Tyr Lys Glu He 165 170 175 Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr 180 185 190 Asn Tyr Leu Thr His Arg Gin Thr Asn Thr He He Asp Val Gin He 195 200 205 Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val Leu 210 215 220 Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gin Met Thr Trp 225 230 235 240 Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg He 245 250 255 Asp Gin Ser Asn Ser His Ala Asn He Phe Tyr Ser Val Leu Thr He 260 265 270 Asp Lys Met Gin Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg 275 280 285 Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His He Tyr Asp 290 295 300 Lys Ala Phe He Thr Val Lys His Arg Lys Gin Gin Val Leu Glu Thr 305 310 315 320 Val Ala Gly Lys Arg Ser Tyr Arg Leu Ser Met Lys Val Lys Ala Phe 325 330 335 Pro Ser Pro Glu Val Val Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu 340 345 350 Lys Ser Ala Arg Tyr Leu Thr Arg Gly Tyr Ser Leu He He Lys Asp 355 360 365 Val Thr Glu Glu Asp Ala Gly Asn Tyr Thr He Leu Leu Ser He Lys 370 375 380 Gin Ser Asn Val Phe Lys Asn Leu Thr Ala Thr Leu He Val Asn Val 385 390 395 400 Lys Pro Gin He Tyr Glu Lys Ala Val Ser Ser Phe Pro Asp Pro Ala 405 410 415 Leu Tyr Pro Leu Gly Ser Arg Gin He Leύ Thr Cys Thr Ala Tyr Gly 420 425 430 He Pro Gin Pro Thr He Lys Trp Phe Trp His Pro Cys Asn His Asn 435 440 445 His Ser Glu Ala Arg Cys Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe 450 455 460 He Leu Asp Ala Asp Ser Asn Met Gly Asn Arg He Glu Ser He Thr 465 470 475 480 ( Gin Arg Met Ala He He Glu Gly Lys Asn Lys Met Ala Ser Thr Leu 485 490 495 Val Val Ala Asp Ser Arg He Ser Gly He Tyr He Cys He Ala Ser 500 505 510 Asn Lys Val Gly Thr Val Gly Arg Asn He Ser Phe Tyr He Thr Asp 515 520 525 Val Pro Asn Gly Phe His Val Asn Leu Glu Lys Met Pro Thr Glu Gly 530 535 540 Glu Asp Leu Lys Leu Ser Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp 545 550 555 560 Val Thr Trp He Leu Leu Arg Thr Val Asn Asn Arg Thr Met His Tyr 565 570 575 Ser He Ser Lys Gin Lys Met Ala He Thr Lys Glu His Ser He Thr 580 585 590 Leu Asn Leu Thr He Met Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr 595 600 605 Ala Cys Arg Ala Arg Asn Val Tyr Thr Gly Glu Glu He Leu Gin Lys 610 615 620 Lys Glu He Thr He Arg Gly Glu His Cys Asn Lys Lys Ala Val Phe 625 630 635 640 Ser Arg He Ser Lys Phe Lys Ser Thr Arg Asn Asp Cys Thr Thr Gin 645 650 655 Ser Asn Val Lys His 660 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 668 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: l near (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13: Ser Gl u Gi n Asn Met Gi n Ser Lys Val Leu Leu Al a Val Ala Leu Trp 1 5 10 15 Leu Cys Val Gl u Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser 20 25 30 Leu Asp Leu Pro Arg Leu Ser He Gin Lys Asp He Leu Thr H e Lys 35 40 45 Ala Asn Thr Thr Leu Gin He Thr Cys Arg Gly Gin Arg Asp Leu Asp 50 55 60 Trp Leu Trp Pro Asn Asn Gin Ser Gly Ser Glu Gin Arg Val Glu Val 65 70 75 80 Thr Glu Cys Ser Asp Gly Leu Phe Cys Lys Thr Leu Thr He Pro Lys 85 90 95 Val He Gly Asn Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr 100 105 110 Asp Leu Ala Ser Val He Tyr Val Tyr Val Gin Asp Tyr Arg Ser Pro 115 120 125 Phe He Ala Ser Val Ser Asp Gin His Gly Val Val Tyr He Thr Glu 130 135 140 Asn Lys Asn Lys Thr Val Val He Pro Cys Leu Gly Ser He Ser Asn 145 150 155 160 Leu Asn Val Ser Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro 165 170 175 Asp Gly Asn Arg He Ser Trp Asp Ser Lys Lys Gly Phe Thr He Pro 180 185 190 Ser Tyr Met He Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys He 195 200 205 Asn Asp Glu Ser Tyr Gin Ser He Met Tyr He Val Val Val Val Gly 210 215 220 Tyr Arg He Tyr Asp Val Val Leu Ser Pro Ser His Gly lie Glu Leu 225 230 235 240 Ser Val Gly Glu Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu 245 250 255 Asn Val Gly He Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gin 260 265 270 His Lys Lys Leu Val Asn Arg Asp Leu Lys Thr Gin Ser Gly Ser Glu 275 280 285 Met Lys Lys Phe Leu Ser Thr Leu Thr He Asp Gly Val Thr Arg Ser 290 295 300 Asp Gin Gly Leu Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys 305 310 315 320 Lys Asn Ser Thr Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe 325 330 335 Gly Ser Gly Met Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val 340 345 350 Arg He Pro Ala Lys Tyr Leu Gly Tyr Pro Pro Pro Glu He Lys Trp 355 360 365 Tyr Lys Asn Gly He Pro Leu Glu Ser Asn His Thr He Lys Ala Gly 370 375 380 His Val Leu Thr He Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr 385 390 395 400 Thr Val He Leu Thr Asn Pro He Ser Lys Glu Lys Gin Ser His Val 405 410 415 Val Ser Leu Val Val Tyr Val Pro Pro Gin He Gly Glu Lys Ser Leu 420 425 430 He Ser Pro Val Asp Ser Tyr Gin Tyr Gly Thr Thr Gin Thr Leu Thr 435 440 445 Cys Thr Val Tyr Ala He Pro Pro Pro His His He His Trp Tyr Trp 450 455 460 Gin Leu Glu Glu Glu Cys Ala Asn Glu Pro Ser Gin Ala Val Ser Val 465 470 475 480 Thr Asn Pro Tyr Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gin 485 490 495 Gly Gly Asn Lys He Ala Val Asn Lys Asn Gin Phe Ala Leu He Glu 500 505 510 Gly Lys Asn Lys Thr Val Ser Thr Leu Val He Gin Ala Ala Asn Val 515 520 525 Ser Ala Leu Tyr Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu 530 535 540 Arg Val He Ser Phe His Val Thr Arg Gly Pro Glu He Thr Leu Gin 545 550 555 560 Pro Asp Met Gin Pro Thr Glu Gin Glu Ser Val Ser Leu Trp Cys Thr 565 570 575 Ala Asp Arg Ser Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro 580 585 590 Gin Pro Leu Pro He His Val Gly Glu Leu Pro Thr Pro Val Cys Lys 595 600 605 Asn Leu Asp Thr Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser 610 615 620 Thr Asn Asp He Leu He Met Glu Leu Lys Asn Ala Ser Leu Gin Asp 625 630 635 640 Gin Gly Asp Tyr Val Cys Leu Ala Gin Asp Arg Lys Thr Lys Lys Arg 645 650 655 His Cys Val Val Arg Gin Leu Thr Val Leu Glu Arg 660 665 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 780 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N0:14: Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser l 5 10 15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro 20 25 30 Glu Leu Ser Leu Lys Gly Thr Gin His He Met Gin Ala Gly Gin Thr 35 40 45 Leu His Leu Gin Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro 50 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser He Thr Lys Ser Ala 65 70 75 80 Cys Gly Arg Asn Gly Lys Gin Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 95 Ala Gi n Ala Asn Hi s Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Al a Val 100 105 110 p r o Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala He Tyr He Phe He 115 120 125 Ser Asp Thr Gly Arg Pro Phe Val Gl u Met Tyr Ser Gl u He Pro Gl u 130 135 140 H e He Hi s Met Thr Gl u Gl y Arg Gl u Leu Val He Pro Cys Arg Val 145 150 155 160 Thr Ser Pro Asn He Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr 165 170 175 Leu He Pro Asp Gly Lys Arg He He Trp Asp Ser Arg Lys Gly Phe 180 185 190 He He Ser Asn Ala Thr Tyr Lys Glu He Gly Leu Leu Thr Cys Glu 195 200 205 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220 Gin Thr Asn Thr He He Asp Val Gin He Ser Thr Pro Arg Pro Val 225 230 235 240 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255 Pro Leu Asn Thr Arg Val Gin Met Thr Trp Ser Tyr Pro Asp Glu Lys 260 265 270 Asn Lys Arg Ala Ser Val Arg Arg Arg He Asp Gin Ser Asn Ser His 275 280 285 Ala Asn He Phe Tyr Ser Val Leu Thr He Asp Lys Met Gin Asn Lys 290 295 300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys 305 310 315 320 Ser Val Asn Thr Ser Val His He Tyr Asp Lys Ala Phe He Thr Val 325 330 335 Lys His Arg Lys Gin Gin Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340 345 350 Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val 355 360 365 Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu 370 375 380 Thr Arg Gly Tyr Ser Leu He He Lys Asp Val Thr Glu Glu Asp Ala 385 390 395 400 Gly Asn Tyr Thr He Leu Leu Ser He Lys Gin Ser Asn Val Phe Lys 405 410 415 Asn Leu Thr Ala Thr Leu He Val Asn Val Lys Pro Gin He Tyr Glu 420 425 430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser 435 440 445 Arg Gin He Leu Thr Cys Thr Ala Tyr Gly He Pro Gin Pro Thr He 450 455 460 Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470 475 480 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe He Leu Asp Ala Asp Ser 485 490 495 Asn Met Gly Asn Arg He Glu Ser He Thr Gin Arg Met Ala He He 500 505 510 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg 515 520 525 He Ser Gly He Tyr He Cys He Ala Ser Asn Lys Val Gly Thr Val 530 535 540 Gly Arg Asn He Ser Phe Tyr He Thr Asp Val Pro Asn Gly Phe His 545 550 555 560 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser 565 570 575 Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp He Leu Leu 580 585 590 Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser He Ser Lys Gin Lys 595 600 605 Met Ala He Thr Lys Glu His Ser He Thr Leu Asn Leu Thr He Met 610 615 620 Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625 630 635 640 Val Tyr Thr Gly Glu Glu He Leu Gin Lys Lys Glu He Thr He Arg 645 650 655 Asp Gin Glu Ala Pro Tyr Leu Leu Arg Asn Leu Ser Asp His Thr Val 660 665 670 Ala He Ser Ser Ser Thr Thr Leu Asp Cys His Ala Asn Gly Val Pro 675 680 685 Glu Pro Gin He Thr Trp Phe Lys Asn Asn His Lys He Gin Gin Glu 690 695 700 Pro Gly He He Leu Gly Pro Gly Ser Ser Thr Leu Phe He Glu Arg 705 710 715 720 Val Thr Glu Glu Asp Glu Gly Val Tyr His Cys Lys Ala Thr Asn Gin 725 730 735 Lys Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gin Gly Thr Ser 740 745 750 Asp Lys Ser Asn Leu Glu Leu He Thr Leu Thr Cys Thr Cys Val Ala 755 760 765 Ala Thr Leu Phe Trp Leu Leu Leu Thr Leu Leu He 770 775 780 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 788 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Gin Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu 1 5 10 15 Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro 20 25 30 Arg Leu Ser He Gin Lys Asp He Leu Thr He Lys Ala Asn Thr Thr 35 40 45 Leu Gin He Thr Cys Arg Gly Gin Arg Asp Leu Asp Trp Leu Trp Pro 50 55 60 Asn Asn Gin Ser Gly Ser Glu Gin Arg Val Glu Val Thr Glu Cys Ser 65 70 75 80 Asp Gly Leu Phe Cys Lys Thr Leu Thr He Pro Lys Val He Gly Asn 85 90 95 Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser 100 105 110 Val He Tyr Val Tyr Val Gin Asp Tyr Arg Ser Pro Phe He Ala Ser 115 120 125 Val Ser Asp Gin His Gly Val Val Tyr He Thr Glu Asn Lys Asn Lys 130 135 140 Thr Val Val He Pro Cys Leu Gly Ser He Ser Asn Leu Asn Val Ser 145 150 155 160 Leu Cys Ala Arg Tyr Pro Glu Lys Arg Phe Val Pro Asp Gly Asn Arg 165 170 175 He Ser Trp Asp Ser Lys Lys Gly Phe Thr He Pro Ser Tyr Met He 180 185 190 Ser Tyr Ala Gly Met Val Phe Cys Glu Ala Lys He Asn Asp Glu Ser 195 200 205 Tyr Gin Ser He Met Tyr He Val Val Val Val Gly Tyr Arg He Tyr 210 215 220 Asp Val Val Leu Ser Pro Ser His Gly He Glu Leu Ser Val Gly Glu 225 230 235 240 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu Asn Val Gly He 245 250 255 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys His Gin His Lys Lys Leu 260 265 270 Val Asn Arg Asp Leu Lys Thr Gin Ser Gly Ser Glu Met Lys Lys Phe 275 280 285 Leu Ser Thr Leu Thr He Asp Gly Val Thr Arg Ser Asp Gin Gly Leu • 2.o9n0 2 -_9_5 300 Tyr Thr Cys Ala Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr 305 310 315 320 Phe Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met 325 330 335 Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg He Pro Ala 340 345 350 Lys Tyr Leu Gly Tyr Pro Pro Pro Glu He Lys Trp Tyr Lys Asn Gly 355 360 365 He Pro Leu Glu Ser Asn His Thr He Lys Ala Gly His Val Leu Thr 370 375 380 He Met Glu Val Ser Glu Arg Asp Thr Gly Asn Tyr Thr Val He Leu 385 390 395 400 Thr Asn Pro He Ser Lys Glu Lys Gin Ser His Val Val Ser Leu Val 405 410 415 Val Tyr Val Pro Pro Gin He Gly Glu Lys Ser Leu He Ser Pro Val 420 425 430 Asp Ser Tyr Gin Tyr Gly Thr Thr Gin Thr Leu Thr Cys Thr Val Tyr 435 440 445 Ala He Pro Pro Pro His His He His Trp Tyr Trp Gin Leu Glu Glu 450 455 460 Glu Cys Ala Asn Glu Pro Ser Gin Ala Val Ser Val Thr Asn Pro Tyr 465 470 475 480 Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gin Gly Gly Asn Lys 485 490 495 He Ala Val Asn Lys Asn Gin Phe Ala Leu He Glu Gly Lys Asn Lys 500 505 510 Thr Val Ser Thr Leu Val He Gin Ala Ala Asn Val Ser Ala Leu Tyr 515 520 525 Lys Cys Glu Ala Val Asn Lys Val Gly Arg Gly Glu Arg Val He Ser 530 535 540 Phe His Val Thr Arg Gly Pro Glu He Thr Leu Gin Pro Asp Met Gin 545 550 555 560 Pro Thr Glu Gin Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser 565 570 575 Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gin Pro Leu Pro 580 585 590 He His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp Thr 595 600 605 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr Asn Asp He 610 615 620 Leu He Met Glu Leu Lys Asn Ala Ser Leu Gin Asp Gin Gly Asp Tyr 625 630 635 640 Val Cys Leu Ala Gin Asp Arg Lys Thr Lys Lys Arg His Cys Val Val 645 650 655 Arg Gin Leu Thr Val Leu Glu Arg Val Ala Pro Thr He Thr Gly Asn 660 665 670 Leu Glu Asn Gin Thr Thr Ser He Gly Glu Ser He Glu Val Ser Cys 675 680 685 Thr Ala Ser Gly Asn Pro Pro Pro Gin He Met Trp Phe Lys Asp Asn 690 695 700 Glu Thr Leu Val Glu Asp Ser Gly He Val Leu Lys Asp Gly Asn Arg 705 710 715 720 Asn Leu Thr He Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Cys 725 730 735 Gin Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe He 740 745 750 He Glu Gly Ala Gin Glu Lys Thr Asn Leu Glu He He He Leu Val 755 760 765 Gly Thr Thr Val He Ala Met Phe Phe Trp Leu Leu Leu Val He He 770 775 780 Leu Gly Thr Val 785 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2264 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (i.i) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GGTGTGGTCG CTGCGTTTCC TCTGCCTGCG CCGGGCATCA CTTGCGCGCC GCAGAAAGTC 60 CGTCTGGCAG CCTGGATATC CTCTCCTACC GGCACCCGCA GACGCCCCTG CAGCCGCGGT 120 CGGCGCCCGG GCTCCCTAGC CCTGTGCGCT CAACTGTCCT GCGCTGCGGG GTGCCGCGAG 180 TTCCACCTCC GCGCCTCCTT CTCTAGACAG GCGCTGGGAG AAAGAACCGG CTCCCGAGTT 240 CCGGCATTTC GCCCGGCTCG AGGTGCAGGA TGCAGAGCAA GGTGCTGCTG GCCGTCGCCC 300 TGTGGCTCTG CGTGGAGACC CGGGCCGCCT CTGTGGGTTT GCCTAGTGTT TCTCTTGATC 360 TGCCCAGGCT CAGCATACAA AAAGACATAC TTACAATTAA GGCTAATACA ACTCTTCAAA 420 TTACTTGCAG GGGACAGAGG GACTTGGACT GGCTTTGGCC CAATAATCAG AGTGGCAGTG 480 AGCAAAGGGT GGAGGTGACT GAGTGCAGCG ATGGCCTCTT CTGTAAGACA CTCACAATTC 540 CAAAAGTGAT CGGAAATGAC ACTGGAGCCT ACAAGTGCTT CTACCGGGAA ACTGACTTGG 600 CCTCGGTCAT TTATGTCTAT GTTCAAGATT ACAGATCTCC ATTTATTGCT TCTGTTAGTG 660 ACCAACATGG AGTCGTGTAC ATTACTGAGA ACAAAAACAA AACTGTGGTG ATTCCATGTC 720 TCGGGTCCAT TTCAAATCTC AACGTGTCAC TTTGTGCAAG ATACCCAGAA AAGAGATTTG 780 TTCCTGATGG TAACAGAATT TCCTGGGACA GCAAGAAGGG CTTTACTATT CCCAGCTACA 840 TGATCAGCTA TGCTGGCATG GTCTTCTGTG AAGCAAAAAT TAATGATGAA AGTTACCAGT 900 CTATTATGTA CATAGTTGTC GTTGTAGGGT ATAGGATTTA TGATGTGGTT CTGAGTCCGT 960 CTCATGGAAT TGAACTATCT GTTGGAGAAA AGCTTGTCTT AAATTGTACA GCAAGAACTG 1020 AACTAAATGT GGGGATTGAC TTCAACTGGG AATACCCTTC TTCGAAGCAT CAGCATAAGA 1080 AACTTGTAAA CCGAGACCTA AAAACCCAGT CTGGGAGTGA GATGAAGAAA TTTTTGAGCA 1140 CCTTAACTAT AGATGGTGTA ACCCGGAGTG ACCAAGGATT GTACACCTGT GCAGCATCCA 1200 GTGGGCTGAT GACCAAGAAG AACAGCACAT TTGTCAGGGT CCATGAAAAA CCTTTTGTTG 1260 CTTTTGGAAG TGGCATGGAA TCTCTGGTGG AAGCCACGGT GGGGGAGCGT GTCAGAATCC 1320 CTGCGAAGTA CCTTGGTTAC CCACCCCCAG AAATAAAATG GTATAAAAAT GGAATACCCC 1380 TTGAGTCCAA TCACACAATT AAAGCGGGGC ATGTACTGAC GATTATGGAA GTGAGTGAAA 1440 GAGACACAGG AAATTACACT GTCATCCTTA CCAATCCCAT TTCAAAGGAG AAGCAGAGCC 1500 ATGTGGTCTC TCTGGTTGTG TATGTCCCAC CCCAGATTGG TGAGAAATCT CTAATCTCTC 1560 CTGTGGATTC CTACCAGTAC GGCACCACTC AAACGCTGAC ATGTACGGTC TATGCCATTC 1620 CTCCCCCGCA TCACATCCAC TGGTATTGGC AGTTGGAGGA AGAGTGCGCC AACGAGCCCA 1680 GCCAAGCTGT CTCAGTGACA AACCCATACC CTTGTGAAGA ATGGAGAAGT GTGGAGGACT 1740 TCCAGGGAGG AAATAAAATT GCCGTTAATA AAAATCAATT TGCTCTAATT GAAGGAAAAA 1800 ACAAAACTGT AAGTACCCTT GTTATCCAAG CGGCAAATGT GTCAGCTTTG TACAAATGTG 1860 AAGCGGTCAA CAAAGTCGGG AGAGGAGAGA GGGTGATCTC CTTCCACGTG ACCAGGGGTC 1920 CTGAAATTAC TTTGCAACCT GACATGCAGC CCACTGAGCA GGAGAGCGTG TCTTTGTGGT 1980 GCACTGCAGA CAGATCTACG TTTGAGAACC TCACATGGTA CAAGCTTGGC CCACAGCCTC 2040 TGCCAATCCA TGTGGGAGAG TTGCCCACAC CTGTTTGCAA GAACTTGGAT ACTCTTTGGA 2100 AATTGAATGC CACCATGTTC TCTAATAGCA CAAATGACAT TTTGATCATG GAGCTTAAGA 2160 ATGCATCCTT GCAGGACCAA GGAGACTATG TCTGCCTTGC TCAAGACAGG AAGACCAAGA 2220 AAAGACATTG CGTGGTCAGG CAGCTCACAG TCCTAGAGCG TTAA 2264 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2352 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17: GCGCTCACCA TGGTCAGCTA CTGGGACACC GGGGTCCTGC TGTGCGCGCT GCTCAGCTGT 60 CTGCTTCTCA CAGGATCTAG TTCAGGTTCA AAATTAAAAG ATCCTGAACT GAGTTTAAAA 120 GGCACCCAGC ACATCATGCA AGCAGGCCAG ACACTGCATC TCCAATGCAG GGGGGAAGCA 180 GCCCATAAAT GGTCTTTGCC TGAAATGGTG AGTAAGGAAA GCGAAAGGCT GAGCATAACT 240 AAATCTGCCT GTGGAAGAAA TGGCAAACAA TTCTGCAGTA CTTTAACCTT GAACACAGCT 300 CAAGCAAACC ACACTGGCTT CTACAGCTGC AAATATCTAG CTGTACCTAC TTCAAAGAAG 360 AAGGAAACAG AATCTGCAAT CTATATATTT ATTAGTGATA CAGGTAGACC TTTCGTAGAG 420 ATGTACAGTG AAATCCCCGA AATTATACAC ATGACTGAAG GAAGGGAGCT CGTCATTCCC 480 TGCCGGGTTA CGTCACCTAA CATCACTGTT ACTTTAAAAA AGTTTCCACT TGACACTTTG 540 ATCCCTGATG GAAAACGCAT AATCTGGGAC AGTAGAAAGG GCTTCATCAT ATCAAATGCA 600 ACGTACAAAG AAATAGGGCT TCTGACCTGT GAAGCAACAG TCAATGGGCA TTTGTATAAG 660 ACAAACTATC TCACACATCG ACAAACCAAT ACAATCATAG ATGTCCAAAT AAGCACACCA 720 CGCCCAGTCA AATTACTTAG AGGCCATACT CTTGTCCTCA ATTGTACTGC TACCACTCCC 780 TTGAACACGA GAGTTCAAAT GACCTGGAGT TACCCTGATG AAAAAAATAA GAGAGCTTCC 840 GTAAGGCGAC GAATTGACCA AAGCAATTCC CATGCCAACA TATTCTACAG TGTTCTTACT 900 ATTGACAAAA TGCAGAACAA AGACAAAGGA CTTTATACTT GTCGTGTAAG GAGTGGACCA 960 TCATTCAAAT CTGTTAACAC CTCAGTGCAT ATATATGATA AAGCATTCAT CACTGTGAAA 1020 CATCGAAAAC AGCAGGTGCT TGAAACCGTA GCTGGCAAGC GGTCTTACCG GCTCTCTATG 1080 AAAGTGAAGG CATTTCCCTC GCCGGAAGTT GTATGGTTAA AAGATGGGTT ACCTGCGACT 1140 GAGAAATCTG CTCGCTATTT GACTCGTGGC TACTCGTTAA TTATCAAGGA CGTAACTGAA 1200 GAGGATGCAG GGAATTATAC AATCTTGCTG AGCATAAAAC AGTCAAATGT GTTTAAAAAC 1260 CTCACTGCCA CTCTAATTGT CAATGTGAAA CCCCAGATTT ACGAAAAGGC CGTGTCATCG 1320 TTTCCAGACC CGGCTCTCTA CCCACTGGGC AGCAGACAAA TCCTGACTTG TACCGCATAT 1380 GGTATCCCTC AACCTACAAT CAAGTGGTTC TGGCACCCCT GTAACCATAA TCATTCCGAA 1440 GCAAGGTGTG ACTTTTGTTC CAATAATGAA GAGTCCTTTA TCCTGGATGC TGACAGCAAC 1500 ATGGGAAACA GAATTGAGAG CATCACTCAG CGCATGGCAA TAATAGAAGG AAAGAATAAG 1560 ATGGCTAGCA CCTTGGTTGT GGCTGACTCT AGAATTTCTG GAATCTACAT TTGCATAGCT 1620 TCCAATAAAG TTGGGACTGT GGGAAGAAAC A AAGCTTTT ATATCACAGA TGTGCCAAAT 1680 GGGTTTCATG TTAACTTGGA AAAAATGCCG ACGGAAGGAG AGGACCTGAA ACTGTCTTGC 1740 ACAGTTAACA AGTTCTTATA CAGAGACGTT ACTTGGATTT TACTGCGGAC AGTTAATAAC 1800 AGAACAATGC ACTACAGTAT TAGCAAGCAA AAAATGGCCA TCACTAAGGA GCACTCCATC 1860 ACTCTTAATC TTACCATCAT GAATGTTTCC CTGCAAGATT CAGGCACCTA TGCCTGCAGA 1920 GCCAGGAATG TATACACAGG GGAAGAAATC CTCCAGAAGA AAGAAATTAC AATCAGAGAT 1980 CAGGAAGCAC CATACCTCCT GCGAAACCTC AGTGATCACA CAGTGGCCAT CAGCAGTTCC 2040 ACCACTTTAG ACTGTCATGC TAATGGTGTC CCCGAGCCTC AGATCACTTG GTTTAAAAAC 2100 AACCACAAAA TACAACAAGA GCCTGGAATT ATTTTAGGAC CAGGAAGCAG CACGCTGTTT 2160 ATTGAAAGAG TCACAGAAGA GGATGAAGGT GTCTATCACT GCAAAGCCAC CAACCAGAAG 2220 GGCTCTGTGG AAAGTTCAGC ATACCTCACT GTTCAAGGAA CCTCGGACAA GTCTAATCTG 2280 GAGCTGATCA CTCTAACATG CACCTGTGTG GCTGCGACTC TCTTCTGGCT CCTATTAACC 2340 CTCCTTATCT AA 2352 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2383 base pairs (B) TYPE : nuclei c aci d (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:18: CTCGAGGTGC AGGATGCAGA GCAAGGTGCT GCTGGCCGTC GCCCTGTGGC TCTGCGTGGA 60 GACCCGGGCC GCCTCTGTGG GTTTGCCTAG TGTTTCTCTT GATCTGCCCA GGCTCAGCAT 120 ACAAAAAGAC ATACTTACAA TTAAGGCTAA TACAACTCTT CAAATTACTT GCAGGGGACA 180 GAGGGACTTG GACTGGCTTT GGCCCAATAA TCAGAGTGGC AGTGAGCAAA GGGTGGAGGT 240 GACTGAGTGC AGCGATGGCC TCTTCTGTAA GACACTCACA ATTCCAAAAG TGATCGGAAA 300 TGACACTGGA GCCTACAAGT GCTTCTACCG GGAAACTGAC TTGGCCTCGG TCATTTATGT 360 CTATGTTCAA GATTACAGAT CTCCATTTAT TGCTTCTGTT AGTGACCAAC ATGGAGTCGT 420 GTACATTACT GAGAACAAAA ACAAAACTGT GGTGATTCCA TGTCTCGGGT CCATTTCAAA 480 TCTCAACGTG TCACTTTGTG CAAGATACCC AGAAAAGAGA TTTGTTCCTG ATGGTAACAG 540 AATTTCCTGG GACAGCAAGA AGGGCTTTAC TATTCCCAGC TACATGATCA GCTATGCTGG 600 CATGGTCTTC TGTGAAGCAA AAATTAATGA TGAAAGTTAC CAGTCTATTA TGTACATAGT 660 TGTCGTTGTA GGGTATAGGA TTTATGATGT GGTTCTGAGT CCGTCTCATG GAATTGAACT 720 ATCTGTTGGA GAAAAGCTTG TCTTAAATTG TACAGCAAGA ACTGAACTAA ATGTGGGGAT 780 TGACTTCAAC TGGGAATACC CTTCTTCGAA GCATCAGCAT AAGAAACTTG TAAACCGAGA 840 CCTAAAAACC CAGTCTGGGA GTGAGATGAA GAAATTTTTG AGCACCTTAA CTATAGATGG 900 TGTAACCCGG AGTGACCAAG GATTGTACAC CTGTGCAGCA TCCAGTGGGC TGATGACCAA 960 GAAGAACAGC ACATTTGTCA GGGTCCATGA AAAACCTTTT GTTGCTTTTG GAAGTGGCAT 1020 GGAATCTCTG GTGGAAGCCA CGGTGGGGGA GCGTGTCAGA ATCCCTGCGA AGTACCTTGG 1080 TTACCCACCC CCAGAAATAA AATGGTATAA AAATGGAATA CCCCTTGAGT CCAATCACAC 1140 AATTAAAGCG GGGCATGTAC TGACGATTAT GGAAGTGAGT GAAAGAGACA CAGGAAATTA 1200 CACTGTCATC CTTACCAATC CCATTTCAAA GGAGAAGCAG AGCCATGTGG TCTCTCTGGT 1260 TGTGTATGTC CCACCCCAGA TTGGTGAGAA ATCTCTAATC TCTCCTGTGG ATTCCTACCA 1320 GTACGGCACC ACTCAAACGC TGACATGTAC GGTCTATGCC ATTCCTCCCC CGCATCACAT 1380 CCACTGGTAT TGGCAGTTGG AGGAAGAGTG CGCCAACGAG CCCAGCCAAG CTGTCTCAGT 1440 GACAAACCCA TACCCTTGTG AAGAATGGAG AAGTGTGGAG GACTTCCAGG GAGGAAATAA 1500 AATTGCCGTT AATAAAAATC AATTTGCTCT AATTGAAGGA AAAAACAAAA CTGTAAGTAC 1560 CCTTGTTATC CAAGCGGCAA ATGTGTCAGC TTTGTACAAA TGTGAAGCGG TCAACAAAGT 1620 CGGGAGAGGA GAGAGGGTGA TCTCCTTCCA CGTGACCAGG GGTCCTGAAA TTACTTTGCA 1680 ACCTGACATG CAGCCCACTG AGCAGGAGAG CGTGTCTTTG TGGTGCACTG CAGACAGATC 1740 TACGTTTGAG AACCTCACAT GGTACAAGCT TGGCCCACAG CCTCTGCCAA TCCATGTGGG 1800 AGAGTTGCCC ACACCTGTTT GCAAGAACTT GGATACTCTT TGGAAATTGA ATGCCACCAT 1860 GTTCTCTAAT AGCACAAATG ACATTTTGAT CATGGAGCTT AAGAATGCAT CCTTGCAGGA 1920 CCAAGGAGAC TATGTCTGCC TTGCTCAAGA CAGGAAGACC AAGAAAAGAC ATTGCGTGGT 1980 CAGGCAGCTC ACAGTCCTAG AGCGTGTGGC ACCCACGATC ACAGGAAACC TGGAGAATCA 2040 GACGACAAGT ATTGGGGAAA GCATCGAAGT CTCATGCACG GCATCTGGGA ATCCCCCTCC 2100 ACAGATCATG TGGTTTAAAG ATAATGAGAC CCTTGTAGAA GACTCAGGCA TTGTATTGAA 2160 GGATGGGAAC CGGAACCTCA CTATCCGCAG AGTGAGGAAG GAGGACGAAG GCCTCTACAC 2220 CTGCCAGGCA TGCAGTGTTC TTGGCTGTGC AAAAGTGGAG GCATTTTTCA TAATAGAAGG 2280 TGCCCAGGAA AAGACGAACT TGGAAATCAT TATTCTAGTA GGCACGACGG TGATTGCCAT 2340 GTTCTTCTGG CTACTTCTTG TCATCATCCT AGGGACCGTT TAA 2383

Claims: WHAT IS CLAIMED IS: 1. A soluble VEGF inhibitor in substantially pure form which specifically binds VEGF and inhibits cellular VEGF receptor activity. 2. The soluble VEGF inhibitor according to Claim 1 wherein the soluble VEGF receptor is selected from the group consisting of sVEGF-RI, sVEGF-RII, sVEGF-RTMI and sVEGF-RTMII. 3. The soluble VEGF inhibitor of Claim 2 corresponding to sVEGF-RI comprising the amino acid sequence: Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gin His He Met Gin Ala Gly Gin Thr Leu His Leu Gin Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser He Thr Lys Ser Ala Cys Gly Arg Asn Gly Lys Gin Phe Cys Ser Thr Leu Thr Leu Asn Thr Ala Gin Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala He Tyr He Phe He Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu He Pro Glu He He His Met Thr Glu Gly Arg Glu Leu Val He Pro Cys Arg Val Thr Ser Pro Asn He Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu He Pro Asp Gly Lys Arg He He Trp Asp Ser Arg Lys Gly Phe He He Ser Asn Ala Thr Tyr Lys Glu He Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gin Thr Asn Thr He He Asp Val Gin He Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gin Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg He Asp Gin Ser Asn Ser His Ala Asn He Phe Tyr Ser Val Leu Thr He Asp Lys Met Gin Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His He Tyr Asp Lys Ala Phe He Thr Val Lys His Arg Lys Gin Gin Val Leu Glu Thr Val Ala Gly Lys Arg Ser Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu Thr Arg Gly Tyr Ser Leu He He Lys Asp Val Thr Glu Glu Asp Ala Gly Asn Tyr Thr He Leu Leu Ser He Lys Gin Ser Asn Val Phe Lys Asn Leu Thr Ala Thr Leu He Val Asn Val Lys Pro Gin He Tyr Glu Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser Arg Gin He Leu Thr Cys Thr Ala Tyr Gly He Pro Gin Pro Thr He Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe He Leu Asp Ala Asp Ser Asn Met Gly Asn Arg He Glu Ser He Thr Gin Arg Met Ala He He Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg He Ser Gly He Tyr He Cys He Ala Ser Asn Lys Val Gly Thr Val Gly Arg Asn He Ser Phe Tyr He Thr Asp Val Pro Asn Gly Phe His Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp He Leu Leu Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser He Ser Lys Gin Lys Met Ala He Thr Lys Glu His Ser He Thr Leu Asn Leu Thr He Met Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn Val Tyr Thr Gly Glu Glu He Leu Gin Lys Lys Glu He Thr He Arg Gly Glu His Cys Asn Lys Lys Ala Val Phe Ser Arg He Ser Lys Phe Lys Ser Thr Arg Asn Asp Cys Thr Thr Gin Ser Asn Val Lys His. (SEQ. ID. NO. : 6) 4. The soluble VEGF inhibitor of Claim 2 corresponding to sVEGF-RI comprising the amino acid sequence: Ser Lys Leu Lys Asp Pro Glu Leu Ser Leu Lys Gly Thr Gin His He Met Gin Ala Gly Gin Thr Leu His Leu Gin Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser He Thr Lys Ser Ala Cys Gly Arg Asn Gly Lys Gin Phe Cyε Ser Thr Leu Thr Leu Asn Thr Ala Gin Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala He Tyr He Phe He Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu He Pro Glu He He His Met Thr Glu Gly Arg Glu Leu Val He Pro Cys Arg Val Thr Ser Pro Asn He Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr Leu He Pro Asp Gly Lys Arg He He Trp Asp Ser Arg Lys Gly Phe He He Ser Asn Ala Thr Tyr Lys Glu He Gly Leu Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg Gin Thr Asn Thr He He Asp Val Gin He Ser Thr Pro Arg Pro Val Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr Pro Leu Asn Thr Arg Val Gin Met Thr Trp Ser Tyr Pro Asp Glu Lys Asn Lys Arg Ala Ser Val Arg Arg Arg He Asp Gin Ser Asn Ser His Ala Asn He Phe Tyr Ser Val Leu Thr He Asp Lys Met Gin Asn Lys Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys Ser Val Asn Thr Ser Val His He Tyr Asp Lys Ala Phe He Thr Val Lys His Arg Lys Gin Gin Val Leu Glu Thr Val Ala Gly Lys Arg Ser Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu Thr Arg Gly Tyr Ser Leu He He Lys Asp Val Thr Glu Glu Asp Ala Gly Asn Tyr Thr He Leu Leu Ser He Lys Gin Ser Asn Val Phe Lys Asn Leu Thr Ala Thr Leu He Val Asn Val Lys Pro Gin He Tyr Glu Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser Arg Gin He Leu Thr Cys Thr Ala Tyr Gly He Pro Gin Pro Thr He Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe He Leu Asp Ala Asp Ser Asn Met Gly Asn Arg He Glu Ser He Thr Gin Arg Met Ala He He Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg He Ser Gly He Tyr He Cys He Ala Ser Asn Lys Val Gly Thr Val Gly Arg Asn He Ser Phe Tyr He Thr Asp Val Pro Asn Gly Phe His Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp He Leu Leu Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser He Ser Lys Gin Lys Met Ala He Thr Lys Glu His Ser He Thr Leu Asn Leu Thr He Met Asn Val Ser Leu Gin Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn Val Tyr Thr Gly Glu Glu He Leu Gin Lys Lys Glu He Thr He Arg Gly Glu His Cys Asn Lys Lys Ala Val Phe Ser Arg He Ser Lys Phe Lys Ser Thr Arg Asn Asp Cys Thr Thr Gin Ser Asn Val Lys His. (SEQ. ID. NO. : 12) 5 . The soluble VEGF inhibitor of Claim 2 corresponding to sVEGF-RII compris ing the amino acid sequence : MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQ DILTIKANTTLQITCRGQR DLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVI YVWQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFV PDGNRISWDS GFTIPSYMISYAGMVFCEAKINDESYQSIMYIWWGYRIYDWL SPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSS BQ___ _KI.VNRD-___α , QSGSEM K_KFLSTLTIDGVTRSDQGLYTCAASSGl-_ITK^ TVGERVRIPAIO-LGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVI LTNPI S EKQSHWSLWYVPPQIGEKSLI SPVDSYQYGTTQTLTCTVYAIPPPHHI HWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGN IAVNi QFALIEGKNKT VSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLW CTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIM EIja.ASLQDQGDWC .QDR_<rπC RHCVVRQLTVLER . ( SEQ . ID . NO . : 13 ) 6. The soluble VEGF inhibitor of Claim 2 corresponding to sVEGF-RTMI comprising the amino acid sequence: MVS WDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEA AHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPT SK_KKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKK FPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNT IIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQS NSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQ VLE AGKRSYRLSMI<^KAFPSPEVV¥LKDGLPATEKSARYLTRGYSLIIKDVTEED AGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTA YGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIE GIOKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEG ED1__KLSCTVNI^LYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVS LQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHA NGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVE SSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLLI. (SEQ. ID. NO. : 14) 7. The soluble VEGF inhibitor of Claim 2 corresponding to sVEGF-RTMII comprising the amino acid sequence: MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQR DLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVI YVYVQDYRSPFIASVSDQHGWYITENKNKTWIPCLGSISNLNVSLCARYPEKRFV PDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIWVVGYRIYDWL SPSHGIELSVGE_α_,VLNCTARTELNVGIDFNWEYPSSCTQHKKLVNlU)LKTQSGSEM KKFLSTLTIDGVTRSDQGLYTCAASSGI_*rTI_ STFVRVHEKPFVAFGSGMESLVEA TVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVI LTNPISKEKQSHWSLWYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHI HWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIAVNKNQFALIEGKNKT VSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLW CTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIM 5 EIJNASLQDQGDYVCI_AQDRiαΕ_KRHCVVRQLTVI_ERVAPTITGNLENQTTSIGESI EVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYCQACSV LGCAKVEAFFIIEGAQEKTNLEIIILVGTTVIAMFFWLLLVIILGTV. (SEQ. ID. NO. : 15) 10 8. An expression vector comprising a promoter, and a DNA sequence encoding a soluble VEGF inhibitor for expression in recombinant host cells wherein the soluble VEGF inhibitor is selected from the group consisting of sVEGF-RI, sVEGF-RII, sVEGF-RTMI and sVEGF-RTMII. 15 9. The expression vector of Claim 8 wherein the DNA encoding the sVEGF-RI comprises the nucleotide sequence 2 0 GCGGACACTCCTCTCGGCTCCTCCCCGGCAGCGGCGGCGGCTCGGAGCGGGCTCCGGGG CTCGGGTGCAGCGGCCAGCGGGCCTGGCGGCGAGGATTACCCGGGGAAGTGGTTGTCTC CTGGCTGGAGCCGCGAGACGGGCGCTCAGGGCGCGGGGCCGGCGGCGGCGAACGAGAGG 5 ACGGACTCTGGCGGCCGGGTCGTTGGCCGGGGGAGCGCGGGCACCGGGCGAGCAGGCCG 0 CGTCGCGCTCACC ATG GTC AGC TAC TGG GAC ACC GGG GTC CTG CTG TGC GCG CTG CTC AGC TGT CTG CTT CTC ACA GGA TCT AGT TCA GGT TCA AAA TTA AAA GAT CCT GAA CTG AGT TTA AAA GGC ACC CAG CAC ATC ATG CAA GCA GGC CAG ACA CTG CAT CTC CAA TGC AGG GGG GAA GCA GCC CAT AAA TGG TCT TTG CCT GAA ATG GTG AGT AAG GAA AGC GAA AGG CTG AGC ATA ACT AAA TCT GCC TGT GGA AGA AAT GGC AAA CAA TTC TGC AGT ACT TTA ACC TTG AAC ACA GCT CAA GCA AAC CAC ACT GGC TTC TAC AGC TGC AAA TAT CTA GCT GTA CCT ACT TCA AAG AAG AAG GAA ACA GAA TCT GCA ATC TAT ATA TTT ATT AGT GAT ACA GGT AGA CCT TTC GTA GAG ATG TAC AGT GAA ATC CCC GAA ATT ATA CAC ATG ACT GAA GGA AGG GAG CTC GTC ATT CCC TGC CGG GTT ACG TCA CCT AAC ATC ACT GTT ACT TTA AAA AAG TTT CCA CTT GAC ACT TTG ATC CCT GAT GGA AAA CGC ATA ATC TGG GAC AGT AGA AAG GGC TTC ATC ATA TCA AAT GCA ACG TAC AAA GAA ATA GGG CTT CTG ACC TGT GAA GCA ACA GTC AAT GGG CAT TTG TAT AAG ACA AAC TAT CTC ACA CAT CGA CAA ACC AAT ACA ATC ATA GAT GTC CAA ATA AGC ACA CCA CGC CCA GTC AAA TTA CTT AGA GGC CAT ACT CTT GTC CTC AAT TGT ACT GCT ACC ACT CCC TTG AAC ACG AGA GTT CAA ATG ACC TGG AGT TAC CCT GAT GAA AAA AAT AAG AGA GCT TCC GTA AGG CGA CGA ATT GAC CAA AGC AAT TCC CAT GCC AAC ATA TTC TAC AGT GTT CTT ACT ATT GAC AAA ATG CAG AAC AAA GAC AAA GGA CTT TAT ACT TGT CGT GTA AGG AGT GGA CCA TCA TTC AAA TCT GTT AAC ACC TCA GTG CAT ATA TAT GAT AAA GCA TTC ATC ACT GTG AAA CAT CGA AAA CAG CAG GTG CTT GAA ACC GTA GCT GGC AAG CGG TCT TAC CGG CTC TCT ATG AAA GTG AAG GCA TTT CCC TCG CCG GAA GTT GTA TGG TTA AAA GAT GGG TTA CCT GCG ACT GAG AAA TCT GCT CGC TAT TTG ACT CGT GGC TAC TCG TTA ATT ATC AAG GAC GTA ACT GAA GAG GAT GCA GGG AAT TAT ACA ATC TTG CTG AGC ATA AAA CAG TCA AAT GTG TTT AAA AAC CTC ACT GCC ACT CTA ATT GTC AAT GTG AAA CCC CAG ATT TAC GAA AAG GCC GTG TCA TCG TTT CCA GAC CCG GCT CTC TAC CCA CTG GGC AGC AGA CAA ATC CTG ACT TGT ACC GCA TAT GGT ATC CCT CAA CCT ACA ATC AAG TGG TTC TGG CAC CCC TGT AAC CAT AAT CAT TCC GAA GCA AGG TGT GAC TTT TGT TCC AAT AAT GAA GAG TCC TTT ATC CTG GAT GCT GAC AGC AAC ATG GGA AAC AGA ATT GAG AGC ATC ACT CAG CGC ATG GCA ATA ATA GAA GGA AAG AAT AAG ATG GCT AGC ACC TTG GTT GTG GCT GAC TCT AGA ATT TCT GGA ATC TAC ATT TGC ATA GCT TCC AAT AAA GTT GGG ACT GTG GGA AGA AAC ATA AGC TTT TAT ATC ACA GAT GTG CCA AAT GGG TTT CAT GTT AAC TTG GAA AAA ATG CCG ACG GAA GGA GAG GAC CTG AAA CTG TCT TGC ACA GTT AAC AAG TTC TTA TAC AGA GAC GTT ACT TGG ATT TTA CTG CGG ACA GTT AAT AAC AGA ACA ATG CAC TAC AGT ATT AGC AAG CAA AAA ATG GCC ATC ACT AAG GAG CAC TCC ATC ACT CTT AAT CTT ACC ATC ATG AAT GTT TCC CTG CAA GAT TCA GGC ACC TAT GCC TGC AGA GCC AGG AAT GTA TAC ACA GGG GAA GAA ATC CTC CAG AAG AAA GAA ATT ACA ATC AGA GGT GAG CAC TGC AAC AAA AAG GCT GTT TTC TCT CGG ATC TCC AAA TTT AAA AGC ACA AGG AAT GAT TGT ACC ACA CAA AGT AAT GTA AAA CAT TAA AGGACTCATTAAAAAGTAACAGTTGTCTCATATCATCTTGATTTATTGTCA • CTGTTGCTAACTTTCAGGCTCGGAGGAGATGCTCCTCCCAAAATGAGTTCGGAGATGAT AGCAGTAATAATGAGACCCCCGGGCTCCAGCTCTGGGCCCCCCATTCAGGCCGAGGGGG CTGCTCCGGGGGGCCGACTTGGTGCACGTTTGGATTTGGAGGATCCCTGCACTGCCTTC TCTGTGTTTGTTGCTCTTGCTGTTTTCTCCTGCCTGATAAACAACAACTTGGGATGATC CTTTCCATTTTGATGCC CCTCTTTTTATTTTTAAGCGGCGCCCTATAGT. (SEQ. ID. NO. : 5) 10. The expression vector of Claim 8 wherein the DNA encoding the sVEGF-RII comprises the nucleotide sequence: GGTGTGGTCGCTGCGTTTCCTCTGCCTGCGCCGGGCATCACTTGCGCGCCGCAGAA AGTCCGTCTGGCAGCCTGGATATCCTCTCCTACCGGCACCCGCAGACGCCCCTGCA GCCGCGGTCGGCGCCCGGGCTCCCTAGCCCTGTGCGCTCAACTGTCCTGCGCTGCG GGGTGCCGCGAGTTCCACCTCCGCGCCTCCTTCTCTAGACAGGCGCTGGGAGAAAG AACCGGCTCCCGAGTTCCGGCATTTCGCCCGGCTCGAGGTGCAGGATGCAGAGCAA GGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCCTCTGTGG GTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTT ACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGA CTGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGT GCAGCGATGGCCTCTTCTGTAAGACACTCACAATTCCAAAAGTGATCGGAAATGAC ACTGGAGCCTACAAGTGCTTCTACCGGGAAACTGACTTGGCCTCGGTCATTTATGT CTATGTTCAAGATTACAGATCTCCATTTATTGCTTCTGTTAGTGACCAACATGGAG TCGTGTACATTACTGAGAACAAAAACAAAACTGTGGTGATTCCATGTCTCGGGTCC ATTTCAAATCTCAACGTGTCACTTTGTGCAAGATACCCAGAAAAGAGATTTGTTCC TGATGGTAACAGAATTTCCTGGGACAGCAAGAAGGGCTTTACTATTCCCAGCTACA TGATCAGCTATGCTGGCATGGTCTTCTGTGAAGCAAAAATTAATGATGAAAGTTAC CAGTCTATTATGTACATAGTTGTCGTTGTAGGGTATAGGATTTATGATGTGGTTCT GAGTCCGTCTCATGGAATTGAACTATCTGTTGGAGAAAAGCTTGTCTTAAATTGTA CAGCAAGAACTGAACTAAATGTGGGGATTGACTTCAACTGGGAATACCCTTCTTCG AAGCATCAGCATAAGAAACTTGTAAACCGAGACCTAAAAACCCAGTCTGGGAGTGA GATGAAGAAATTTTTGAGCACCTTAACTATAGATGGTGTAACCCGGAGTGACCAAG GATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAGAACAGCACATTT GTCAGGGTCCATGAAAAACCTTTTGTTGCTTTTGGAAGTGGCATGGAATCTCTGGT GGAAGCCACGGTGGGGGAGCGTGTCAGAATCCCTGCGAAGTACCTTGGTTACCCAC CCCCAGAAATAAAATGGTATAAAAATGGAATACCCCTTGAGTCCAATCACACAATT AAAGCGGGGCATGTACTGACGATTATGGAAGTGAGTGAAAGAGACACAGGAAATTA ° CACTGTCATCCTTACCAATCCCATTTCAAAGGAGAAGCAGAGCCATGTGGTCTCTC TGGTTGTGTATGTCCCACCCCAGATTGGTGAGAAATCTCTAATCTCTCCTGTGGAT TCCTACCAGTACGGCACCACTCAAACGCTGACATGTACGGTCTATGCCATTCCTCC CCCGCATCACATCCACTGGTATTGGCAGTTGGAGGAAGAGTGCGCCAACGAGCCCA GCCAAGCTGTCTCAGTGACAAACCCATACCCTTGTGAAGAATGGAGAAGTGTGGAG 5 GACTTCCAGGGAGGAAATAAAATTGCCGTTAATAAAAATCAATTTGCTCTAATTGA AGGAAAAAACAAAACTGTAAGTACCCTTGTTATCCAAGCGGCAAATGTGTCAGCTT TGTACAAATGTGAAGCGGTCAACAAAGTCGGGAGAGGAGAGAGGGTGATCTCCTTC CACGTGACCAGGGGTCCTGAAATTACTTTGCAACCTGACATGCAGCCCACTGAGCA GGAGAGCGTGTCTTTGTGGTGCACTGCAGACAGATCTACGTTTGAGAACCTCACAT ° GGTACAAGCTTGGCCCACAGCCTCTGCCAATCCATGTGGGAGAGTTGCCCACACCT GTTTGCAAGAACTTGGATACTCTTTGGAAATTGAATGCCACCATGTTCTCTAATAG CACAAATGACATTTTGATCATGGAGCTTAAGAATGCATCCTTGCAGGACCAAGGAG ACTATGTCTGCCTTGCTCAAGACAGGAAGACCAAGAAAAGACATTGCGTGGTCAGG CAGCTCACAGTCCTAGAGCGTTAA. (SEQ. ID. NO.: 16) 5 11. The expression vector of Claim 8 wherein the DNA encoding the sVEGF-RTMI comprises the nucleotide sequence: ° GCGCTCACCATGGTCAGCTACTGGGACACCGGGGTCCTGCTGTGCGCGCTGCTCAG CTGTCTGCTTCTCACAGGATCTAGTTCAGGTTCAAAATTAAAAGATCCTGAACTGA GTTTAAAAGGCACCCAGCACATCATGCAAGCAGGCCAGACACTGCATCTCCAATGC AGGGGGGAAGCAGCCCATAAATGGTCTTTGCCTGAAATGGTGAGTAAGGAAAGCGA AAGGCTGAGCATAACTAAATCTGCCTGTGGAAGAAATGGCAAACAATTCTGCAGTA CTTTAACCTTGAACACAGCTCAAGCAAACCACACTGGCTTCTACAGCTGCAAATAT CTAGCTGTACCTACTTCAAAGAAGAAGGAAACAGAATCTGCAATCTATATATTTAT TAGTGATACAGGTAGACCTTTCGTAGAGATGTACAGTGAAATCCCCGAAATTATAC ACATGACTGAAGGAAGGGAGCTCGTCATTCCCTGCCGGGTTACGTCACCTAACATC ACTGTTACTTTAAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAAAACGCAT ° AATCTGGGACAGTAGAAAGGGCTTCATCATATCAAATGCAACGTACAAAGAAATAG GGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAAGACAAACTATCTC ACACATCGACAAACCAATACAATCATAGATGTCCAAATAAGCACACCACGCCCAGT CAAATTACTTAGAGGCCATACTCTTGTCCTCAATTGTACTGCTACCACTCCCTTGA ACACGAGAGTTCAAATGACCTGGAGTTACCCTGATGAAAAAAATAAGAGAGCTTCC 5 GTAAGGCGACGAATTGACCAAAGCAATTCCCATGCCAACATATTCTACAGTGTTCT TACTATTGACAAAATGCAGAACAAAGACAAAGGACTTTATACTTGTCGTGTAAGGA GTGGACCATCATTCAAATCTGTTAACACCTCAGTGCATATATATGATAAAGCATTC ATCACTGTGAAACATCGAAAACAGCAGGTGCTTGAAACCGTAGCTGGCAAGCGGTC TTACCGGCTCTCTATGAAAGTGAAGGCATTTCCCTCGCCGGAAGTTGTATGGTTAA ° AAGATGGGTTACCTGCGACTGAGAAATCTGCTCGCTATTTGACTCGTGGCTACTCG TTAATTATCAAGGACGTAACTGAAGAGGATGCAGGGAATTATACAATCTTGCTGAG CATAAAACAGTCAAATGTGTTTAAAAACCTCACTGCCACTCTAATTGTCAATGTGA AACCCCAGATTTACGAAAAGGCCGTGTCATCGTTTCCAGACCCGGCTCTCTACCCA CTGGGCAGCAGACAAATCCTGACTTGTACCGCATATGGTATCCCTCAACCTACAAT 5 CAAGTGGTTCTGGCACCCCTGTAACCATAATCATTCCGAAGCAAGGTGTGACTTTT GTTCCAATAATGAAGAGTCCTTTATCCTGGATGCTGACAGCAACATGGGAAACAGA ATTGAGAGCATCACTCAGCGCATGGCAATAATAGAAGGAAAGAATAAGATGGCTAG CACCTTGGTTGTGGCTGACTCTAGAATTTCTGGAATCTACATTTGCATAGCTTCCA ATAAAGTTGGGACTGTGGGAAGAAACATAAGCTTTTATATCACAGATGTGCCAAAT ° GGGTTTCATGTTAACTTGGAAAAAATGCCGACGGAAGGAGAGGACCTGAAACTGTC TTGCACAGTTAACAAGTTCTTATACAGAGACGTTACTTGGATTTTACTGCGGACAG TTAATAACAGAACAATGCACTACAGTATTAGCAAGCAAAAAATGGCCATCACTAAG GAGCACTCCATCACTCTTAATCTTACCATCATGAATGTTTCCCTGCAAGATTCAGG CACCTATGCCTGCAGAGCCAGGAATGTATACACAGGGGAAGAAATCCTCCAGAAGA AAGAAATTACAATCAGAGATCAGGAAGCACCATACCTCCTGCGAAACCTCAGTGAT CACACAGTGGCCATCAGCAGTTCCACCACTTTAGACTGTCATGCTAATGGTGTCCC CGAGCCTCAGATCACTTGGTTTAAAAACAACCACAAAATACAACAAGAGCCTGGAA TTATTTTAGGACCAGGAAGCAGCACGCTGTTTATTGAAAGAGTCACAGAAGAGGAT GAAGGTGTCTATCACTGCAAAGCCACCAACCAGAAGGGCTCTGTGGAAAGTTCAGC ° ATACCTCACTGTTCAAGGAACCTCGGACAAGTCTAATCTGGAGCTGATCACTCTAA CATGCACCTGTGTGGCTGCGACTCTCTTCTGGCTCCTATTAACCCTCCTTATCTAA . (SEQ. ID. NO. : 17) 12. The expression vector of Claim 8 wherein the DNA 5 encoding the sVEGF-RTMII comprises the nucleotide sequence: CTCGAGGTGCAGGATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCG TGGAGACCCGGGCCGCCTCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGG 0 CTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATACAACTCTTCAAATTAC TTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGTG AGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGTAAGACACTCACA ATTCCAAAAGTGATCGGAAATGACACTGGAGCCTACAAGTGCTTCTACCGGGAAAC TGACTTGGCCTCGGTCATTTATGTCTATGTTCAAGATTACAGATCTCCATTTATTG 5 CTTCTGTTAGTGACCAACATGGAGTCGTGTACATTACTGAGAACAAAAACAAAACT GTGGTGATTCCATGTCTCGGGTCCATTTCAAATCTCAACGTGTCACTTTGTGCAAG ATACCCAGAAAAGAGATTTGTTCCTGATGGTAACAGAATTTCCTGGGACAGCAAGA AGGGCTTTACTATTCCCAGCTACATGATCAGCTATGCTGGCATGGTCTTCTGTGAA GCAAAAATTAATGATGAAAGTTACCAGTCTATTATGTACATAGTTGTCGTTGTAGG ° GTATAGGATTTATGATGTGGTTCTGAGTCCGTCTCATGGAATTGAACTATCTGTTG GAGAAAAGCTTGTCTTAAATTGTACAGCAAGAACTGAACTAAATGTGGGGATTGAC TTCAACTGGGAATACCCTTCTTCGAAGCATCAGCATAAGAAACTTGTAAACCGAGA CCTAAAAACCCAGTCTGGGAGTGAGATGAAGAAATTTTTGAGCACCTTAACTATAG ATGGTGTAACCCGGAGTGACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTG ATGACCAAGAAGAACAGCACATTTGTCAGGGTCCATGAAAAACCTTTTGTTGCTTT TGGAAGTGGCATGGAATCTCTGGTGGAAGCCACGGTGGGGGAGCGTGTCAGAATCC CTGCGAAGTACCTTGGTTACCCACCCCCAGAAATAAAATGGTATAAAAATGGAATA CCCCTTGAGTCCAATCACACAATTAAAGCGGGGCATGTACTGACGATTATGGAAGT GAGTGAAAGAGACACAGGAAATTACACTGTCATCCTTACCAATCCCATTTCAAAGG ° AGAAGCAGAGCCATGTGGTCTCTCTGGTTGTGTATGTCCCACCCCAGATTGGTGAG AAATCTCTAATCTCTCCTGTGGATTCCTACCAGTACGGCACCACTCAAACGCTGAC ATGTACGGTCTATGCCATTCCTCCCCCGCATCACATCCACTGGTATTGGCAGTTGG AGGAAGAGTGCGCCAACGAGCCCAGCCAAGCTGTCTCAGTGACAAACCCATACCCT TGTGAAGAATGGAGAAGTGTGGAGGACTTCCAGGGAGGAAATAAAATTGCCGTTAA 5 TAAAAATCAATTTGCTCTAATTGAAGGAAAAAACAAAACTGTAAGTACCCTTGTTA TCCAAGCGGCAAATGTGTCAGCTTTGTACAAATGTGAAGCGGTCAACAAAGTCGGG AGAGGAGAGAGGGTGATCTCCTTCCACGTGACCAGGGGTCCTGAAATTACTTTGCA ACCTGACATGCAGCCCACTGAGCAGGAGAGCGTGTCTTTGTGGTGCACTGCAGACA GATCTACGTTTGAGAACCTCACATGGTACAAGCTTGGCCCACAGCCTCTGCCAATC ° CATGTGGGAGAGTTGCCCACACCTGTTTGCAAGAACTTGGATACTCTTTGGAAATT GAATGCCACCATGTTCTCTAATAGCACAAATGACATTTTGATCATGGAGCTTAAGA ATGCATCCTTGCAGGACCAAGGAGACTATGTCTGCCTTGCTCAAGACAGGAAGACC AAGAAAAGACATTGCGTGGTCAGGCAGCTCACAGTCCTAGAGCGTGTGGCACCCAC GATCACAGGAAACCTGGAGAATCAGACGACAAGTATTGGGGAAAGCATCGAAGTCT 5 CATGCACGGCATCTGGGAATCCCCCTCCACAGATCATGTGGTTTAAAGATAATGAG ACCCTTGTAGAAGACTCAGGCATTGTATTGAAGGATGGGAACCGGAACCTCACTAT CCGCAGAGTGAGGAAGGAGGACGAAGGCCTCTACACCTGCCAGGCATGCAGTGTTC TTGGCTGTGCAAAAGTGGAGGCATTTTTCATAATAGAAGGTGCCCAGGAAAAGACG AACTTGGAAATCATTATTCTAGTAGGCACGACGGTGATTGCCATGTTCTTCTGGCT 0 ACTTCTTGTCATCATCCTAGGGACCGTTTAA. (SEQ. ID. NO.: 18) 13. A recombinant host cell containing the expression vector of Claim 8. 14. A method for inhibiting VEGF receptor function comprising the administration of the VEGF inhibitor of Claim 1 in an amount sufficient to inhibit VEGF receptor function. 15. The method of Claim 14 wherein the VEGF inhibitor is selected from the group consisting of sVEGF-RI, sVEGF-RII, sVEGF-RTMI, and sVEGF-RTMII. 16. A pharmaceutical composition comprising the inhibitor of Claim 1 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of Claim 16 wherein the inhibitor is selected from the group consisting of sVEGF-RI, sVEGF-RII, sVEGF-RTMI, and sVEGF-RTMII. 18. A method for inhibiting angiogenesis comprising the administration of the VEGF inhibitor of Claim 1 in an amount sufficient to inhibit angiogensis.

Inventors: KENDALL RICHARD L, THOMAS KENNETH A JR, KENDALL, RICHARD, L., THOMAS, KENNETH, A., JR.
Applicants: KENDALL RICHARD L, MERCK & CO INC, THOMAS KENNETH A JR, KENDALL, RICHARD, L., MERCK & CO., INC., THOMAS, KENNETH, A., JR.
Application year: 1994
Main classification: C07K13
IPC codes: A61K38, A61P9, A61P43, C07K14, C12N5, C12N15, C12P21, C12R1